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ABSTRACT 
It is well documented that mortality rates have decreased and the survival of HIV and AIDS 
patients has been prolonged since the introduction of highly active antiretroviral therapy (HAART) 
in 1996.  Although HAART has dramatically improved the prognosis of HIV disease, some HIV 
patients on HAART still die of HIV related illnesses. It is important to understand what these 
factors are in order to mitigate the impact on these factors on patient survival and achieve better 
outcome for these patients. The aim of this study was to determine risk factors for long term 
survival of patients on HAART in Uganda. 
 
Data for 2,244 out of 30,000 clients receiving care and treatment at TASO Entebbe was 
retrospectively analyzed. TASO Entebbe is a non-governmental HIV clinic that provides care and 
treatment to HIV positive clients. Long term survival in this case was defined as survival for more 
than 5 years after initiation on HAART. Logistic regression and survival analysis were conducted.  
 
Female clients had a 12% lower risk of death compared to the male clients (AHR=0.88 [CI: 0.443-
0.936]). Clients that had pulmonary TB had 1.3 times higher risk of death compared to clients that 
did not have pulmonary TB (AHR=1.33 [CI: 1.162-2.733]). Clients initiated at CD4 cell counts 
less than 250 cells/μl had almost 7 times higher adjusted odds of death compared to those initiated 
at CD4 cell counts greater than 500 cells/μl (AOR= 6.95 [CI: 2.882-16.744]) and clients initiated 
at CD4 cell counts between 250 cells/μl   and 500 cells/μl almost 3 times higher adjusted odds of 
death compared to clients initiated at CD4 cell counts greater than 500 cells/μl (AOR 2.56 [CI: 
1.004-6.520]). 
 
It is recommended that an aggressive HIV testing strategy be put in place to facilitate early 
identification of HIV positive patients.  Early identification would enable early initiation into 
HAART well before the CD4 cell counts fall below 500 cells/μl. The observed higher risk of 
mortality amongst men suggests interventions to promote early HIV testing and treatment 
initiation amongst men.  The observed high risk of mortality for patients with pulmonary TB, calls 
for aggressive TB case finding and treatment of positive in order to reduce the HIV/TB related 
mortality.   
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CHAPTER ONE 
INTRODUCTION  
1.1  Background 
HIV/AIDS remains an important public health problem despite significant efforts worldwide to 
combat the disease (Pavlova-McCalla et al., 2012). In 2014, approximately 36.9 million people 
worldwide were thought to be infected with HIV. The vast majority of this number live in low- 
and middle- income countries (AIDSinfo, 2014). Sub-Saharan Africa is the most affected region, 
with 25.8 million people living with HIV in 2014; which accounts for almost 70% of the total new 
HIV infections globally (WHO, 2014). Although the global HIV prevalence is estimated at 0.8% 
in 2014, there are variations across regions ranging from a low of 0.1% in the Middle East and 
North Africa to a high of 4.8% in sub-Saharan Africa (WHO, 2014). Left untreated, HIV/AIDS is 
inevitably fatal, with a median survival time from sero-conversion of 8 to 10 years (Sabin, 2013). 
It is well known that mortality rates have decreased and survival of HIV patients has been 
prolonged since the introduction of highly active antiretroviral therapy (HAART) in 1996 (Stein 
et al., 2006; Murphy et al., 2001; Hogg et al., 1999).  
HAART has dramatically changed the prognosis of HIV disease (Jaggy et al., 2003) and the 
clinical benefits of HAART for HIV/AIDS patients, in terms of mortality reduction and improved 
quality of life is well documented (Braitstein et al., 2006; Egger et al., 2002). In resource-poor 
countries, access to antiretroviral therapy (ART) has improved between 2009 and 2014 and 
mortality rates among treated patients have declined substantially (Azin, 2010).  In 2014, 14.9 
million people living with HIV were receiving antiretroviral therapy (ART) globally, of which 
13.5 million were receiving ART in low- and middle-income countries (WHO, 2014). This 
achievement has been mainly due to two reasons:  
i) reduction of the cost of anti-retroviral (ARV) drugs which led to an increase in access 
and availability of HIV treatment in Sub-Saharan Africa;   
ii) the implementation of WHO guidelines promoting scaling-up by task shifting for 
clinical decision-making to less specialised health-care workers facilitated increases in 
provision of both care and treatment to HIV patients (Gilks et al., 2006).  
HIV patients are now surviving longer and it has been noted that long-term survival in HIV-
positive populations with access to effective HIV prevention, care and treatment appears to be 
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approaching that of the general population (van Sighem et al., 2010). This was observed in a large 
study in rural South Africa, which showed that adult life expectancy rose from 49.2 years in 2003 
(before ART became widely available) to 60.5 years in 2011 (Bor, Herbst, Newell, & 
Bärnighausen, 2013). Studies have shown declining rates of HIV-related deaths compared to non-
HIV related deaths since the introduction of HAART (Lohse et al., 2007; d’Arminio et al., 2007).  
The annual number of people dying from HIV-related causes has decreased by 29% in recent years 
from 1.7 million in 2009 to 1.2 million in 2014 (WHO, 2014). However, the number of HIV related 
deaths is still high compared to other regions: 66% of the global HIV related deaths occur in sub-
Saharan Africa.  
 
Treatment of patients with HIV/AIDS is complex with chronic pathologies associated with 
immunodeficiency, chronic viral infection and socio-behavioral factors (McManus et al., 2012). 
These pathologies include opportunistic infections, neoplasms and organ systems pathologies that 
affect patients with HIV/AIDS (Levy, 2009). The severity of these pathologies depends on the 
level of immunity of the patients, with patients having lower immunity experiencing worse 
outcomes. Observational cohort studies have shown that the probability of staying alive on 
HAART largely depends on adherence to treatment and the degree of immunodeficiency at the 
time of HAART initiation (McManus et al., 2012). In particular patients that adhere to treatment 
have been known to have better prognosis. While biomedical factors associated with long term 
survival of patients on ART are well documented, socio-economic and behavioral factors are not 
well documented. Beyond clinical parameters, pre-existing characteristics of individuals such as 
demographics, socioeconomic status, mental disorders or substance abuse might also affect the  
rate of recovery after ART initiation, and therefore survival. 
 
Like other countries in sub-Saharan Africa, Uganda continues to bear a huge burden of HIV/AIDS 
with an estimated 1.6 million people living with HIV/AIDS in 2014 (UNAIDS, 2014).   In Uganda 
the ART coverage was about 76.5% in 2013 for adults while the provision of cotrimoxazole 
prophylaxis to prevent opportunistic infections has a higher coverage (94%).  Despite this high 
coverage of patients on ART, about 63,000 persons living with HIV (PLHIV) were estimated to 
have died of AIDS-related causes in 2012. In Uganda, HIV positive patients are initiated on 
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HAART based on CD4 cell counts cut off of 350 cell/μl, WHO clinical stage, hemoglobin level 
and the total lymphocyte count.  
 
1.2 Problem Statement  
Since the introduction of HAART there are reductions in HIV-related deaths, as well as increased 
life expectancy for newly diagnosed HIV patients.  One reason for this increase, is the scale up of 
HAART enabling eligible HIV access and initiate HAART promptly.  Although HAART has 
improved the survival of HIV infected patient, compared to patients in high-income countries, 
patients in resource-poor countries have higher mortality rates (Shibre, Bekele, & Abera, 2014).  
To minimize such HIV related deaths, there is need to identify risk factors and potential causes of 
death. Existing knowledge of factors associated with survival of HIV patients has majorly been 
done in patients not yet initiated on HAART.  The studies have also mostly focused on relatively 
small cohorts, and that were followed over a short time period. In addition, the few studies done 
in sub-Saharan Africa have been conducted on patients managed by public health facilities.  Better 
knowledge of prognostic factors would allow closer follow-up of and more targeted interventions 
for HIV positive patient initiated on HAART; thus reducing excess mortality. There is need 
therefore to understand factors associated with survival for patients that have been initiated into 
HAART particularly in a non-government health facility setting. 
 
1.3 Outline of the thesis 
A brief background to the study and the research problem that the study sought to investigate was 
presented in chapter 1. Literature in relation to survival of HIV positive patients initiated in 
HAART, the conceptual framework that guided the study, aims and objectives of the study are 
presented in chapter 2.  The methodology used, study population, data management, analysis and 
the ethical consideration are presented in chapter 3. The results from the analysis of patient data  
are presented in chapters 4 and 5: univariate and bivariate analysis are presented in chapter 4 while 
results from the multivariate models fitted to the data are presented in chapter 5.  In chapter 6 the 
discussion of results and recommendations are presented.   
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            CHAPTER TWO 
LITERATURE REVIEW 
2.1  Introduction 
This chapter presented a review of literature pertaining to factors associated with survival of HIV 
positive patients initiated into HAART. In the first part a review of literature around the 
relationship between different demographic factors, socio-economic factors and behavioral factors 
and clinical factors and survival on HAART is presented.  The focus then shifts to the second part 
which reviews literature on the conceptual framework that was used in the current study. 
 
Knowledge on HIV/AIDS and factors that predict long term survival of HIV infected patients 
initiated on HAART are changing rapidly (AIDSinfo, 2014). Although factors that determine 
mortality in patients before the introduction of HAART are well documented, the effects of these 
factors with the introduction of HAART especially in resource poor settings have not been fully 
investigated. The factors that have been found to affect mortality for patients on ART include: 
viral load, CD4 cell counts, total lymphocytes, body mass index (BMI) and adherence. Although 
these factors tend to be similar across the world, there are some striking differences in their relative 
frequency between well-resourced and resource-poor settings.  
 
2.1  Demographic factors associated with survival on HIV treatment 
Studies have shown that survival on ART is affected by a number of demographic factors.  On 
the whole mixed results have been found. Highlighted below are findings of various studies with 
regards to how demographic factors affect survival of patients on HAART. 
 
2.1.1 Gender 
Studies have shown mixed results in relation to the association of gender and survival of patients 
on HAART have been found.  For example, a study in a rural health center in Cameroon found 
that male subjects had almost double the risk for mortality compared to females (HR 1.73; 1.37–
2.19) (Isidore et al., 2009).  Several authors described gender differences in ART outcomes 
(Sterling et al., 2001; Moore et al., 2002; Kremer & Sonnenberg-Schwan 2003; Perez-Hoyos et 
al., 2003), while others found no gender differences associated with ART (Egger et al., 2002; 
Bourgeois et al., 2005; Nicastri et al., 2005; Braitstein et al., 2006).  Potential factors that have 
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been found to contribute to gender differences in relation to survival on HAART include 
differences in treatment adherence, risk behavior, financial accessibility, and early access to 
antiretroviral treatment (Le Coeur et al., 2007), which could all explain better survival.  Especially 
for men stigma, family and work responsibilities may impact access to treatment. Consequently, 
men are more immune compromised at HAART initiation compared to women (Cornell et al., 
2009).   
 
2.1.2 Age 
Age at diagnosis and age at ART initiation have been found to be associated with the rate and 
extent of immunologic recovery (Li et al., 2011). The effects of aging on survival therefore need 
to be considered in addition to the effects of increased duration of illness (McManus et al., 2012). 
There remains a need to better understand long-term survival in aging. It has been found that the 
relative risk of death within 5 years after an HIV diagnosis was greater for persons who were older 
at the time of diagnosis compared to those who were younger (Jevtović et al., 2007).  However, 
this effect was more evident for patients with CD4 cell counts less than 350 cells/μl compared to 
patients with CD4 cell counts of greater than 350 cells/μl. Studies have also found that age at sero-
conversion seems to have become a less important prognostic factor for progression to AIDS since 
the introduction of HAART (Jevtović et al., 2007). This is perhaps surprising since reconstitution 
of immune function is likely to be more difficult in older people given that clients over the age of 
50 years are less likely to have their CD4 cell counts increased when receiving HAART (Steinman, 
1986, Grabar et al., 2004). 
 
2.2  Socioeconomic factors  
Studies observing populations before the introduction of HAART found that socioeconomic 
factors were not significantly associated with HIV-related mortality (Pavlova-McCalla et al., 
2012). In the post-HAART period various socioeconomic factors were inconsistently associated 
with HIV/AIDS mortality risk in studies adjusting for HAART use. Queries whether the social and 
economic situations of HIV-infected individuals explain variations in the disease progression and 
survival are supported by the framework of social production of disease and political economy of 
health (Pavlova-McCalla et al., 2012). According to this framework, a person’s relative social and 
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economic positioning shapes behavior, and the relationship between subordinate-dominant groups 
affects patterns of disease through material and social inequalities (Zierler & Krieger, 1997). 
 
2.3  Behavioral factors  
The behavioral factors that have been found to be associated with survival on ART include use 
of alcohol and other drugs as well as tobacco use. 
 
2.3.1 Alcohol and other drugs use 
Studies of alcohol use in HIV infected patients have resulted in conflicting and limited information 
regarding prevalence, as well as the effects of alcohol use on HIV replication, disease progression 
and response to ART (Maria et al,. 2003). Heavy alcohol users receiving antiretroviral therapy 
were twice as likely to have CD4 cell counts below 500 cells/μl  compared to light or non-drinkers 
(OR 2.31 [95% CI: 1-5.5] and HAART-treated heavy alcohol users were four times less likely to 
achieve a positive virological response (OR 4.13 [95% CI, 1.2-17] (Maria et al., 2003). Henrich et 
al. (2007) examined association of alcohol abuse and injection drug use (IDU) with the 
immunologic and virological responses to highly active antiretroviral treatment (HAART) in urban 
community health clinics.  In a linear regression model adjusted for age, gender, and baseline CD4 
cell count, history of IDU only and a combination of alcohol abuse and IDU were associated with 
a lesser increase in CD4 cell count after HAART compared with those with neither alcohol nor 
IDU.  The possible reason for this is that alcohol consumption may impact response to 
antiretroviral therapy through its alterations of immune responses, augmented by nutritional 
deficiencies that can further compromise the immune system, as well as its potential effect on 
adherence to treatment (Maria et al., 2003). 
 
2.3.2 Tobacco use 
Chronic manifestations such as cancers or cardiovascular diseases are becoming an emerging 
problem among HIV-infected persons in industrialized countries (Lewden et al., 2005).  Tobacco 
consumption in HIV/AIDS patients from industrialized countries has been shown to be elevated 
and higher than in the general population with approximately half of patients being regular 
smokers (Antoine et al., 2009). Recent reports emphasized that tobacco industries are entering 
actively the market of low-resource countries, including Africa, in order to compensate for their 
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losses in the Northern Hemisphere at a time when the demand in these countries is decreasing 
(Cherif, 2005). Tobacco smoking is associated with poorer response to antiretroviral therapy and 
worse disease progression in HIV/AIDS patients especially women (Reynolds, 2009). An analysis 
of 924 participants starting HAART in women's Interagency HIV study showed that women who 
smoked cigarettes had poorer virological and immunological response to HAART, lower CD4 cell 
counts, higher HIV viral loads, a 36% greater likelihood of developing AIDS-defining illnesses, 
and a 53% higher risk of death compared with non-smokers. The rate of specifically AIDS-related 
death was similar (Feldman et al., 2006). The authors concluded that some of the benefits provided 
by HAART are not revealed in cigarette smokers, and emphasized the need for smoking cessation 
efforts targeting HIV positive women (Feldman et al., 2006).  In a study conducted by the 
University of Miami, the researcher found that HIV positive smokers response to HAART 
decreased by 40% as measured through drug levels in the body, CD4 cell counts and viral loads.  
 
2.4 Clinical factors  
HIV RNA (viral load) and CD4 T lymphocyte (CD4) cell counts are the two surrogate markers of 
antiretroviral treatment (ART) responses and HIV disease progression that have been used for 
decades to manage and monitor HIV infection (AIDSinfo, 2014). In the case of viral load, patient’s 
pre-ART viral load level and the magnitude of viral load decline after initiation of ART provide 
prognostic information about the probability of disease progression CD4 cell counts provides 
information on the overall immune function of an HIV-infected patient (Murray, Elashoff, Iacono-
Connors, Cvetkovich, & Struble, 1999). The measurement is critical in establishing thresholds for 
the initiation and discontinuation of opportunistic infection prophylaxis and in assessing the 
urgency to initiate ART (AIDSinfo, 2014). 
 
2.4.1 Baseline CD4 cell counts at HIV Diagnosis 
CD4 cell count is an important immunologic marker of progression of HIV infection and a key 
predictor of mortality (Egger et al., 2002; WHO, 2006). CD4 cell counts should be measured in all 
patients at entry into care. It is the key factor in determining the need to initiate opportunistic 
infection prophylaxis. The current World Health Organization treatment guidelines recommend 
initiation of ART before the CD4 cell counts reaches less than 500 cells/μl (WHO, 2013). A study 
in Serbia showed that the proportion of patients with a baseline CD4 cell counts below 100 cells/μl 
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at HIV diagnosis were 6 times more likely to die compared to those that had CD4 cell counts 
greater than 100 cells/μl (OR = 6.2  [CI: 1.8-21.0]) (Jevtović et al., 2007).  Another study conducted 
in Durban, South Africa, indicates that CD4 cell counts below 50 cell/µl at diagnosis was the 
strongest predictor of mortality in HIV patients after they started ART (Ojukutu et al., 2008).  
Studies have also found that mortality was roughly two times higher for patients who began ART 
with a severe immune-depression (CD4 cell counts less than 50 cell/μl) (Isidore et al., 2009; 
Kabugo et al., 2005; Laurent et al., 2005b; Sterne et al., 2005; Crum et al., 2006; Etard et al., 2006; 
Kheang, 2006; Egger, 2007).  It has been noted that patients starting treatment at low counts 
probably never reach CD4 cell counts anywhere near normal. This adds to the weight of evidence 
that starting treatment earlier, before CD4 cell counts falls below 350 cells/μl could lead to better 
survival (Huges et al., 2007).  The level of CD4 cell count at the commencement of HAART has 
an impact on immunological recovery, with higher CD4 cell counts resulting into favorable 
treatment outcomes.  
 
2.4.2 WHO staging 
The clinical staging and case definition of HIV for resource-constrained settings were developed 
by the WHO in 1990 and revised in 2007. Staging is based on clinical findings that guide the 
diagnosis, evaluation, and management of HIV/AIDS, and it does not require a CD4 cell counts. 
This staging system is used in many countries to determine eligibility for antiretroviral therapy, 
particularly in settings in which CD4 cell counts testing is not available. Clinical stages are 
categorized as 1 through 4, progressing from primary HIV infection to advanced HIV/AIDS. WHO 
staging of patients at initiation have been found to be associated with survival; for example, a study 
in Ethiopia to determine survival and predictors of mortality among adult patients on HAART 
found that WHO stage 4 at baseline was an independent predictor of survival (Tadele et al., 2014). 
Similar findings have been reported in other studies in Tanzania and Cameron in which patients 
who enrolled into HAART at WHO stage 4 had twice the hazard of death (Johannessen et al., 
2008; Sieleunou et al., 2009) compared to patients enrolled into HAART at WHO stage 1.  
 
2.4.3 Opportunistic infections  
When a patient’s CD4 cell counts fall below 200 cells/μl, opportunistic infections with bacteria 
and other pathogens become common (Janeway et al., 2005). Koenig et al., (2009) found that 
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patients with AIDS who receive a diagnosis of TB during the first months after ART initiation had 
a mortality rate of 27%, which was 3 times higher than that among other patients.  According to 
Manosuthi et al., (2006), patients who were initiated into ART more than 6 months after TB 
diagnosis had higher mortality rate than those who initiated ART less than 6 months after TB 
diagnosis. A study conducted in Durame Hospital, Ethiopia, showed that patients with positive TB 
test had 3.9 times higher risk of death compared to patients with negative TB test results  
(Gezahegu, 2011). 
 
There are many opportunistic infections and co-infections that impose significant burdens of 
morbidity and mortality; among the most important are Hepatitis B (Hoffmann and Thio, 2007), 
Hepatitis C (Rockstroh and Spengler, 2004) and Human herpesvirus-8 (strongly associated with 
Kaposi sarcoma) (Malope et al., 2007). Perhaps the two most important co-infections to consider 
in sub-Saharan Africa are tuberculosis (TB) and malaria (WHO, 2007).    
 
2.4.4 Viral Load 
Viral load has been considered one of the most important indicator of initial and sustained response 
to ART and should be measured in all HIV-infected patients at entry into care, at initiation of 
therapy, and on a regular basis thereafter (AIDSinfo, 2014). A systematic review of data from 
clinical trials involving thousands of participants established that decreases in viral load following 
initiation of ART are associated with reduced risk of progression to AIDS or death (Marschner et 
al., 1998).   
 
2.4.5 ART Regimen 
Antiretroviral drugs currently comprise six distinct classes and over 20 individual agents. The 
nucleoside analogues, or nucleoside reverse transcriptase inhibitors (NRTIs), were the first class 
of Anti-Retroviral (ARV) agents that were developed (Portsmouth, Stebbing and Gazzard 2003). 
The ARVs worked by inhibiting reverse transcriptase enzymes that support the multiplication of 
the virus. So when inhibited the virus cannot multiply. The two additional classes of ARVs in 
routine use are protease inhibitors, which act by inhibiting the cleaving of HIV particles from host 
cells (Wynn et al., 2004), and non-nucleoside reverse transcriptase inhibitors (NNRTIs), which 
bind directly to and thus inhibit reverse transcriptase. A study to evaluate long-term survival of 
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HIV-infected patients treated with HAART in Serbia and Montenegro found that the use of 
regimens containing protease inhibitors and two non-nucleoside reverse transcriptase inhibitors 
was associated with long-term survival (OR 9.0, 95% CI 2.2-35.98) (Jevtović et al., 2007). 
Simultaneous use of all three drug classes was also predictive of long-term survival (OR 7.4, 95% 
CI 2.2-25.1). In the same study, long time survivors took more drugs and had more regimen 
switching than patients who died. Use of HAART composed of three nucleoside reverse 
transcriptase inhibitors or nucleoside reverse transcriptase inhibitors with a non-nucleoside 
reverse transcriptase inhibitors did not lead to difference in survival between subgroups (Jevtović 
et al., 2007). 
 
2.4.6 Cotrimoxazole prophylaxis 
Being put on cotrimoxazole prophylaxis was found to improve the survival probability of the 
patients on HAART significantly (Tadele, Shumey, & Hiruy, 2014). This could be due to the 
benefit from cotrimoxazole in the prevention of the classic opportunistic infections, such as 
Pneumocystis pneumonia, toxoplasmosis, bacterial pneumonia sepsis and diarrhea (Mermin et al., 
2004). The same study also found that daily cotrimoxazole prophylaxis was associated with 
reduced morbidity and mortality and had beneficial effects on CD4 cell counts and viral load. 
 
2.4.7 Body Mass Index 
Malnutrition is a significant factor affecting human immunodeficiency virus (HIV) care and 
treatment in resource limited settings (Semba, Darnton-Hill, & De-Pee, 2010). Adequate diet is 
believed to be important for adherence to antiretroviral therapy (ART) as patients with inadequate 
nutrient intake are known to have more frequent opportunistic infections compared to patients with 
adequate food intake. A study in Zambia shown that provision of food assistance to HIV-infected 
adults on ART had an incentivizing effect which can improve medication adherence, particularly 
among patients recently initiated on treatment (Tirivayi, Koethe, & Groot, 2012).  Lack of essential 
micronutrients in particular contributes to the depletion and dysfunction of CD4 cells counts and 
malnourished patients may have suboptimal response to treatment when (ART) is initiated  
(Koethe, Jenkis, Shepherd, Stinnette, & Sterling, 2011).  BMI is an integral part of anthropometric 
assessments, a widely used indicator to assess nutritional status (Frid, Thors, Rosenblad, & 
Nydahl, 2013). A study conducted in rural Malawi showed that individuals who were severely 
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malnourished defined as BMI less than 16 kg/m2 had six times higher risk of dying compared to 
patients with BMI greater than 16 kg/m2 (Zachariah et al., 2006). Similar results were observed in 
a study conducted in Cameroon showed that BMI less than 18 kg/ m2 had three times higher risk 
of death than patients with BMI greater than 18.5 kg/m2. In a study conducted in Ethiopia, a BMI 
less or equal to 18.5 kg/m2 was significantly associated with overall mortality. A BMI between 15 
and 18.5 kg ⁄ m 2 was related to a 1.5 times higher risk of death compared to BMI greater than 18.5 
kg ⁄m2 (HR = 1.57). This risk rose to three times more for those with a BMI less than 15 kg ⁄ m2 
(Degu et al., 2006).  
 
2.4.8 Hemoglobin levels 
A study in Ethiopia found that anemia was a strong predictor of mortality among adult patients on 
HAART (Shibre et al., 2014). A study conducted in Tanzania shows anemia as a strong predictor 
of mortality; patients with severe anemia had nearly 15 times higher risk of dying during the first 
year on ART as compared to those with a normal hemoglobin level (Asgeir et al., 2008). In 
Malawi, patients with hemoglobin levels less than 8.5 g/dl had two times more risk of death 
compared with patients with hemoglobin level greater than 8.5 g/dl (Zachariah et al., 2006).  
 
2.4.9 Adherence to HAART 
According to published research from the United States, HAART adherence predicts treatment 
response and progression to AIDS and death (Kitahata et al., 2004). Findings showed that higher 
levels of adherence to HAART were significantly associated with longer time to virologic failure, 
greater increase in CD4 cell counts and lower risk of progression to clinical AIDS or death (Fielden 
et al., 2008; Gross et al., 2006; Kitahata et al., 2004).  After controlling for other factors, patients 
with low adherence had over five times the risk of disease progression than patients with moderate 
adherence or patients with high adherence. There was no significant difference in the risk of 
progression between patients with moderate and high levels of adherence. Patients who progressed 
to AIDS or death had significantly higher viral loads and lower CD4 cell counts than patients who 
experienced virological failure, but did not progress, the authors concluded (Kitahata et al., 2004). 
Poor adherence at the initiation of HAART had significant association with mortality in this study 
which was congruent with previous study conducted in Addis Ababa (Bedru & Worku, 2010) and 
Malawi (Zachariah et al., 2006). Researches also revealed that good adherence was significantly 
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correlated with high general health perception scores, and overall quality of life component scores 
(Abrogoua et al., 2012). Although adherence to HAART has been associated with optimal viral 
suppression, the impact of different levels of adherence on long-term clinical outcomes has not 
been determined. 
 
2.5 Conceptual Framework 
The conceptual framework used to guide the study explains the interaction between the 
independent intermediate and the dependent/expected outcome in the study (Figure 1). The 
independent variable comprises of dimensions that include the demographic, socio economic 
factors of the study population, the intermediate factors include biomedical and behavioral factors 
that interact with the demographic and social economic factors to determine survival of the patients 
on HAART.  It was assumed that the biomedical factors and behavioral factors act as intermediate 
variables that affected the survival of patients on HAART.  
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Independent Variables  Intermediate Variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Conceptual Framework 
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            CHAPTER THREE 
METHODOLOGY 
3.1  Study design 
Secondary data of patient data accessing HIV care and treatment at the TASO Entebbe clinic was 
performed. The TASO Entebbe client database contains information of over 30,000 HIV positive 
clients that access HIV services at the clinic. The data used for the study was extracted from the 
TASO HIV patient database for only 2,244 clients that have enrolled into HAART. Data in relation 
to HIV treatment is collected over the patient’s lifetime. TASO was selected for this study because 
it was one of the first HIV care and treatment center in Uganda to provide ARV to HIV patients. 
The study was based on the cohort of HIV-infected patients initiated on HAART at the TASO 
center from June 2004 to June 2014.   
 
3.2  Study Setting 
TASO is an indigenous HIV/AIDS service organization in Uganda founded in 1987 (TASO, 2013). 
The premise on which TASO was found was based on people that were unified by common 
experiences faced when encountering HIV/AIDS at a time of high stigma, ignorance and 
discrimination. TASO has since evolved into a Non-Governmental Organization with eleven 
service centres and four (4) regional offices, covering most parts of Uganda.   Through the years, 
TASO has cared for a cumulative number of over 300,000 PLHIV and has provided support to 
over 1,000,000 members of their families in form of economic empowerment, provision if school 
fees and food support. Out of the total number of PLHIV under the care of TASO, 66,851 are 
receiving life prolonging Anti-retroviral drugs (ARV). The study population were patients in the 
in one of the centres: Entebbe TASO centre.  The selection of this centre was based on its proximity 
to the student.  
3.3  Aim of the study 
The aim of this study was to determine risk factors associated with long term survival of patients 
on HAART in TASO Entebbe in Uganda. 
The objectives of the study were: 
1. To determine demographic factors associated with long term survival of patients on 
HAART. 
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2. To determine socioeconomic factors associated with long term survival of patients on 
HAART. 
3. To determine biomedical factors associated with long term survival of patients on 
HAART. 
4. To determine how changes in key biomedical parameter impact on survival of patients on 
HAART. 
 
3.4  Study population and sampling 
TASO Entebbe has over 30,000 clients in care. In order to satisfy the 10year cohort criteria, the 
study sample was selected from clients that had been initiated into HAART between 2004 and 
2005. A total of 2,244 clients had been initiated on HAART during this period.  The sample size 
was determined based on difference in mortality rates between 2 groups (LTS and STS).  The 
parameters used was based on a study in Taiwan (Fang et al., 2006) where it was found that 5-year 
survival rate was 58% in patients who had already developed AIDS at diagnosis (AIDS group), 
and 89% in those who had not (non-AIDS group).  In order to determine factors associated with 
survival the sample size n is given by: 
        n= Z2[p(1-p)]/e2 
n is the required sample size 
p null hypothesis proportion=0.58 
e required size of standard error: using significance=1.96; SE = 0.05 
This gives a sample size of 374 patients  
 
Inclusion criteria 
 Patients who are 15 years and older. 
 Patients that have been initiated HAART between 2004 to 2005 
 Patients that are still accessing care and have not been lost to follow up 
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3.5  Data collection 
Two TASO client databases, one consisting of demographic socioeconomic and the other clinical 
data of patients receiving HIV care and treatment services at TASO Entebbe clinic was used in 
this study.  The database containing clinical data of the patients was much larger since it contained 
data on clinical outcomes of the clients collected over the years. In order to create the dataset used 
for this study, the two data sets were merged using patient unique identification numbers in the 
two files.  
 
3.5.1  Dependent variables 
The date of initiation into HAART was defined as the date in which the patient was started on 
HAART at TASO center.  This date has been selected because the study focused on survival on 
HAART.  Therefore, to have a uniform definition of the start dates, the date thus of initiation on 
HAART was used. Two dependent variables were analyzed: survival status and survival time. 
3.5.1.1 Survival status 
Patients were grouped into 2 categories:  
1    – If still alive on HAART after 5 years;  
0 – if died before being 5 years on HAART  
 
3.5.1.2 Survival time 
Survival time can be broadly defined as the time to the occurrence of a given event of interest, in 
the case of this study the death of a person. The survival time for a patient initiated on HAART 
(measured in days) was defined as the number of days from the date of initiation on HAART to 
the date of death or end of the study period, which was 31st June 2014.   
 
3.5.2  Independent variables 
The independent variables in the study included: demographic, socioeconomic, and behavioral and 
clinic characteristics of the study population. Under the demographic characteristics, gender, age 
at diagnosis, age at initiation of HAART, distance from the health facility, marital status and 
pregnancy was collected. Under the socio-economic characteristics, type of employment, religion 
and the highest level of education attained by the patients.  Under the behavioral characteristics, 
alcohol, drug use and tobacco use were collected, under the clinical factors CD4 cell counts at 
 
 
 
 
  
17 
 
diagnosis, CD4 cell counts at initiation, adherence defined as monthly ARV medication refill rates, 
opportunistic infections including TB, cancer including kaposi sarcoma, cryptococci meningitis, 
ART regime and hemoglobin was collected.  
3.6  Data Analysis 
Data from the TASO database was extracted into an excel sheet.  This was the imported into 
SAS software in which all the analysis was done 
 
Descriptive analysis of the client included in this study was conducted. Factors analyzed included 
demographic, social economic, behavioral and medical characteristic of the selected respondents. 
Frequency distributions for categorical variables were computed while means, median and inter 
quartile range were computed for continuous variables.    
 
For the fixed period analysis, the outcome variable was defined by the survival status of the clients, 
1- if client is still alive 5 years after initiation into HAART;  
0 - if clients died within 5 years after initiation into HAART  
 
With this definition a dichotomous variable was created and used as the depended variable in the 
analysis.  Contingency table analysis was employed at the bivariate stage of analysis to determine 
the association between the various categorical independent variables. Chi-square statistic used to 
test the hypothesis of equality of survival between the survival status of patients, across levels of 
each demographic, socio-economic and health variables. For continuous independent variables t-
test was used to determine the factors associated with survival. The hypothesis of equal survival 
for groups was rejected if the observed level of significance, p, was less than 0.05. 
 
The Kaplan-Meier or the Product Limit method was used in the bivariate analysis of survival time.  
Survival time defined as the number of days from the date of the patient's HAART initiation to the 
date of death. Cases that were still alive and those lost to the follow-up were considered censored 
observations.  
 
Two models were used in the multivariate analysis in this study: a logistic regression model was 
used to determine factors associated with survival in the fixed period survival of patients initiated 
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on HAART: the Cox proportional hazards model was used to determine the factors associated with 
survival time. 
 
At the multivariate level, the logistic regression to identify variables associated with survival 
status. The logistic model handles cases when the survival time is discrete or known only for a few 
discrete intervals (Hosmer et al., 1989). With HAART survival having significantly increased, a 
five year fixed period was selected for this study. Since fixed period survival times is the outcome 
variable the logistic regression model is the most appropriate for the analysis.  
 
The dependent variable, y, is binary defined by: 
𝑦 =  {
1   𝑖𝑓 𝑑𝑒𝑎𝑑 𝑤𝑖𝑡ℎ𝑖𝑛 𝑓𝑖𝑣𝑒 𝑦𝑒𝑎𝑟𝑠 𝑜𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
0     𝑠𝑡𝑖𝑙𝑙  𝑎𝑙𝑖𝑣𝑒 𝑓𝑖𝑣𝑒 𝑦𝑒𝑎𝑟𝑠 𝑎𝑓𝑡𝑒𝑟 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
 
The major short coming of the logistic regression model is its failure to take into consideration 
censored observations.  The model is applied to a situation where full period of the event is fully 
observed which was not the case in this study. The model also assumes fixed follow-up periods. 
Due to these shortcomings of the logistic regression model which is that it cannot analysed 
censored data (people still alive at the end of the study), a Cox regression model was also used to 
assess factors associated with survival times on HAART.  
 
The Cox proportional hazards model was used to identify variables associated with survival time.  
These response variables in turn depended on a variety of factors (predictors). For this study, the 
response variable was the survival time, measured in days from the date of HAART initiation to 
the date of death or censorship (if lost to follow-up or alive by June 2014).  
  
3.7  Reliability and Validity 
Reliability refers to dependability or a way a tool such as the questionnaire produce similar results 
in different circumstances if nothing changes (Sarantakos, 1998). While validity is an indication 
of the extent to which an instrument measures what we think it is supposed to measure (Sarantakos, 
1998).  For this study, the data extraction tool was designed by the researcher to collect information 
in regard to the study objectives.  The data was also extracted by the researcher herself to ensure 
reliability.  
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3.8  Generalizability 
Since TASO provides the same standard of care as any other facilities providing ART care and 
treatment, these finding can be generalized to other settings within Uganda. 
 
3.9  Ethics considerations 
Ethics clearance to conduct this study was obtained from the Senate Research Committee of 
University of Western Cape and the TASO Research Ethics Committee. Permission for data 
abstraction was obtained from TASO. Although secondary data was used, privacy and 
confidentiality and data protection rules were adhered to throughout the study. No harm was 
anticipated harm to the clients in this study since names or personal identification numbers of 
HIV/AIDS patients were not included in the data extraction sheet (Appendix 1).  After signing a 
confidentiality clause with TASO, the student was allowed to extract patient data with the 
assistance of the TASO data Manager.   
 
Although the results of this study may not have direct benefit to individual patients, on the whole, 
these results may be used to improve care for patients initiated on HAART by providing a criterion 
for identifying patients that may be predisposed to short term survival, thus improving HIV 
programming and patient management at TASO as a whole. 
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CHAPTER FOUR 
RESULTS 
4.1 Introduction 
From the client database, 31,701 clients accessed HIV services at the TASO center, with a total of 
8,441 clients initiated on ART. In order to obtain a 10 year cohort required for this study, only the 
number of clients initiated into HAART between 2004 and 2005 were considered: giving a total 
of 2,648 clients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Patient Acquisition Flow Chart 
 
4.1.1 Sociodemographic characteristics of the study respondents  
Tables 4.1 shows the sociodemographic characteristics of the study respondents. There were more 
females than males in the study (64% vs. 36%). The majority (54.8%) of the clients had an upper 
primary level of education; 28.6% has secondary school level of education, 4.7% tertiary level 
education; while 11.8% had no education. With regard to the marital status, 44% reported being 
married; 24% separated and 23% were widowed. Most of the clients reported their religion as 
Christian (76%), with 43% identifying as Catholic and 33% as Anglican; while Muslims and other 
religions accounted for 23% of the clients.  Just under a quarter (24%) of the clients were 
unemployed, with the others stating their employment status as housewives (4%), peasants, 
Total number of clients in care 
31,701 
2,648 initiated between 2004 - 2005 
2,244 included in the study 
Excluded: 404 < 15 years 
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engaged in subsistence farming (11%), vendors (16%) and paid employees (12%), casual laborers 
(28.2%) and students (0.6%). With regards to the distance to the clinic; majority of the clients 
(63%) resided within 20 km from the clinic, 19.2% resided within 21-35 km from the clinic; 13.4% 
resided within 36-75 km and 5% resided over 75 km from the clinic. The mean age of clients in 
the study was 36 years with the majority (77%) between 25-44 years of age.  The same trend was 
observed for the age at initiation in which about 90% of the clients initiated were aged between 
25-54 years. Only 4% of the patients reported ever having used tobacco in the past, no client 
reported that they were currently using tobacco and only 7% of the clients used alcohol and drugs.  
 
4.1.2 Clinical Characteristics of the study respondents 
Table 4.2 shows the clinical characteristics of the study respondents. The median time between 
diagnosis and initiation on HAART was 309 days, with an interquartile range (IQR) of 78-785 
days. More than half the clients diagnosed with HIV/AIDS (55%) were initiated into ART within 
one year; 19% were initiated within 1-2 years after diagnosis, and 27% more than two years after 
diagnosis. In general, 60% of the clients who were diagnosed with HIV at this clinic had low CD4 
cell counts less than 250 cells/µl). In this study, CD4 cell counts change was defined as the 
difference between highest CD4 cell counts attained by the client after initiation and client CD4 
cell counts at HAART initiation.  Based on the CD4 cell counts change, 62% of the clients 
achieved CD4 cell counts change greater than 250 cell/µl.  
 
The majority of clients (89.7%) had normal hemoglobin levels (greater than 8g/dl). The majority 
of clients were also on first line ART regimens (96%). The majority of the clients (73.6%) were 
on ZDV/3TC based regimen, 13% on TD4/3TC and 11% of the clients were on DT4/3TC were 
11%, Most clients (87%) reported optimal adherence to ART.  The reasons given by the 13% of 
the clients who reported poor adherence included: forgetting to take the drugs (42%), stock outs 
(31%); side-effects (10%); medicine fatigue (6%); toxicity (4%) and provider instruction to stop 
taking medication (2%).  A quarter of clients reported having experienced side effects over the 
course of ART: neuropathy (71%); anemia (15%), rashes (15%); and jaundice (2%).   
 
Majority of the clients in the study (85%) reported having had an opportunistic infection. Preurigo 
was the commonest opportunistic infections (69%); followed by oral candidiasis (36%), 
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pulmonary TB (27%), esophageal candidiasis (16%), cryptococci meningitis (6.2%), 
toxoplasmosis (5%), kaposi sarcoma (2.3%) and pneumocystis pneumonia (1%).  
 
Of all the clients, 53% reported having used family planning, with condoms being the commonest 
type of family planning methods (71%), followed by depo provera (17%); and permanent methods 
(1%). With regards to pregnancy, 30% of the female clients got pregnant of which only 20% 
reported having enrolled into PMTCT.   
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Table 4.1 Sociodemographic character ristics of the study respondents (N=2,244) 
Characteristics                         n                      % 
 
Gender Female 1,439 64.1 
Male 805 35.9 
Education None 260 11.8 
Primary level 1,208 54.8 
Senior  Secondary level 630 28.6 
Tertiary Level 104 4.7 
Marital status Single 136 6.2 
Married 983 44.7 
Separated 532 24.2 
Divorced 36 1.6 
Widowed 514 23.4 
Religion Anglican 723 33.5 
Catholic 922 42.7 
Muslim 248 11.5 
Other 268 12.4 
Type of employment None 465 24.0 
Casual Laborer 546 28.2 
Housewife 73 3.8 
Paid Employee 214 11.1 
Peasant 221 11.4 
Student 11 0.6 
Vendor 318 16.4 
Other 86 4.5 
Distance to health facility (in 
km) 
1-5 405 18.6 
6-10 506 23.3 
11-20 457 21.0 
21-35 417 19.2 
36-75 292 13.4 
>75 98 4.5 
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Characteristics                         n                      % 
 
Age at diagnosis (years) 15-24 179 8.0 
25-34 942 42.0 
35-44 782 34.9 
45-54 251 11.1 
55+ 90 4.0 
Age at ART initiation (years) 15-24 115 5.2 
25-34 857 38.4 
35-44 864 38.5 
45-54 300 13.2 
55+ 108 4.8 
Used tobacco  Yes 34 4.1 
Used alcohol and drugs  Yes 167 7.4 
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Table 4.2: Clinical characteristics of th e study respondents (N=2,244) 
Characteristics n % 
Length of time between 
diagnosis and ART initiation (in 
years) 
<1  1226 54.6 
1-2  418 18.6 
>2  600 26.8 
Baseline CD4 cell counts 
(cells/μl) 
<250 1335 59.6 
250-500 615 27.4 
500+ 219 13.0 
CD4 cell counts change 
(cells/μl) 
<100  242 13.8 
100<250  422 24.1 
250-500 360 20.5 
500+ 730 41.6 
Baseline hemoglobin (g/dl) <8 185 10.3 
8+ 1619 89.7 
ART Regimen D4T/3TC 238 10.6 
TD4/3TC 294 13.1 
ZDV/3TC 1721 76.3 
ART adherence Yes 1952 87.0 
Reason for missing ART 
dosage 
Forgot 68 3.0 
Stock out 50 2.2 
Side effects 6 0.3 
Provider instruction 3 0.1 
Medicine fatigue 9 0.4 
Other reasons 16 0.7 
Experienced ART side-effects Yes 579 25.8 
Side effects Anemia 86 14.9 
Neuro 411 71.1 
Jaundice 4 0.7 
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Characteristics n % 
Rash 85 14.7 
Had opportunistic Infections Yes 1897 84.5 
Pulmonary TB Yes 598 26.7 
Had Extra-pulmonary TB Yes 85 3.8 
Had  Preurigo Yes 1548 69.0 
Had Cryptococci Yes 139 6.2 
Had Kaposi Sarcoma Yes 51 2.3 
Had Esophagus  Candida Yes 351 15.6 
Had Oral Candida Yes 800 35.7 
Had Pneumocystis Pneumonia  Yes 25 1.1 
Had Toxoplasmosis Yes 106 4.7 
Client on Family planning Yes 1187 52.90 
Type of Family planning Condoms 853 71.96 
Implants 32 2.7 
Injection 200 16.9 
Other types of FP 21 1.8 
Permanent 6 0.5 
Pill 75 6.3 
Client Pregnant Yes 441 30.7 
Client on PMTCT Yes 86 19.50 
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4.2 Univariate Analysis 
At the univariate level, two models were fitted to the data: the logistic model using fixed period 
survival (5 years) and the Cox regression model (for survival time) each of the demographic and 
socioeconomic factors of the respondents were individually fitted into the model to assess 
individual association with survival outcomes.  
 
4.2.1 Logistic Regression 
Logistic regression model was fitted to the data to assess the association between the respondent 
characteristic and five-year survival. The odds ratios were used to assess the probability of 
mortality compared to the reference category. All tests were conducted at 5%.   
 
4.2.1.1 Five-year survival by sociodemographic characteristics of the study respondents 
Table 4.3 shows five-year survival by sociodemographic characteristics of ART clients. Female 
clients had 39% lower odds of death within 5 years after initiation into ART compared to the male 
clients (OR=0.61; CI: 0.48-0.78). Clients who ever used tobacco had 4 time higher odds of death 
compared to those that never used tobacco (OR =3.91 [CI: 1.96-7.89]).  No significant associations 
were observed between education, religion, marital status, type of employment, age at diagnosis 
with HIV, age at initiation on HAART, having used alcohol and drugs and death within 5 years. 
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Table 4.3: Five-year survival by sociodemographic characteristics of the study respondents 
(N=2,244) 
                             Characteristics Dead within 5 
years (%) 
(n=315) 
Alive after 5 
years (%) 
(n=1,929) 
Crude Odds Ratio 
(95% Confidence 
interval) 
Gender Female 54.0 46.0 *0.610 (0.479-0.776) 
Male 65.8 34.2 Ref 
Education None 12.4 11.7 Ref 
Primary level 55.7 54.7 0.963(0.659-1.409) 
Secondary level 28.0 28.7 0.924(0.611-1.395) 
Tertiary Level 3.9 4.9 0.762(0.381-1.524) 
Marital status Single 6.8 6.1 1.218(0.716-2.072) 
Married 46.1 44.4 1.136(0.831-1.552) 
Separated 22.9 24.4 1.028(0.718-1.470) 
Divorced 2.6 1.5 1.906(0.834-4.357) 
Widowed 21.6 23.6 Ref 
Religion Anglican 31.4 33.8 0.801(0.542-1.184) 
Catholic 42.8 42.6 0.867(0.596-1.261) 
Muslim 11.8 11.4 0.889(0.549-1.437) 
Other 14.1 12.1 Ref 
Type of 
employment 
None 25.8 22.8 1.409(0.912-2.175) 
Casual Laborer 31.8 27.7 1.491(0.979-2.270) 
Housewife 3.8 3.8 1.283(0.604-2.728) 
Paid Employee 10.5 11.2 1.217(0.716-2.068) 
Peasant 9.7 11.7 1.078(0.629-1.849) 
Student 1.1 0.4 3.032(0.769-11.964) 
Vendor 13.1 17.0 Ref 
Other 4.1 4.5 1.186(0.575-2.445) 
Distance to 
health facility 
(km) 
1-5 22.5 18.0 1.775(0.878-3.588) 
6-10 20.9 21.0 1.389(0.689-2.800) 
11-20 17.6 19.4 1.406(0.694-2.848) 
21-35 12.9 13.5 1.280(0.627-2.616) 
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                             Characteristics Dead within 5 
years (%) 
(n=315) 
Alive after 5 
years (%) 
(n=1,929) 
Crude Odds Ratio 
(95% Confidence 
interval) 
36-75 22.5 22.3 1.356(0.650-2.829) 
>75 3.3 4.7 Ref 
Age at 
diagnosis 
(years) 
15-24 6.0 8.3 *0.475 (0.235-0.959) 
25-34 41.6 42.0 0.646 (0.373-1.118) 
35-44 34.9 34.8 0.655 (0.376-1.140) 
45-54 11.8 11.1 0.692 (0.371-1.290) 
55+ 5.7 3.7 Ref 
Age at ART 
initiation 
(years) 
15-24 4.8 5.2 0.803(0.379-1.700) 
25-34 36.2 38.5 0.821(0.472-1.429) 
35-44 39.7 38.3 0.905(0.522-1.572) 
45-54 14.0 13.3 0.920(0.501-1.691) 
55+ 5.4 4.7 Ref 
Used tobacco  Yes 4.1 1.1 3.9111(1.93-7.89) 
Used alcohol 
and drugs  
Yes 9.5 90.5 1.377(0.9098-2.0838) 
 
4.2.1.2 Five-year survival by clinical characteristics of the study respondents 
Table 4.4 shows five-year survival by clinical characteristics of ART clients. No significant 
differences were observed between lengths of time between diagnosis and initiation to HAART 
and CD4 at diagnosis and the odds of death. In relation to baseline CD4 clients, clients who has a 
CD4 cell count less than 250 cells/μl had 13 times higher odds of death (OR= 12.721 [CI: 5.607-
28.858]) compared to clients with a baseline CD4 of greater than 500 cells/μl. Clients who has a 
CD4 cell count between 250 cells/μl and 500 cells/μl had 2 times higher odds of death (OR= 2.181 
[CI: 0.890-5.342]) compared to clients with a baseline CD4 of greater than 500 cells/μl, however 
this was not significantly different.  
 
Clients who had a CD4 cell count change of between 100-250 cells/μl had 83% lower odds of 
death (OR= 0.171 [CI: 0.085-0.344]) compared to clients with a CD4 cell count change of less 
than 100 cells/μl. Clients who has a CD4 cell count change of between 250 cells/μl and 500 cells/μl 
had 94% lower odds of death (OR= 0.064 [CI: 0.023-0.175]) compared to clients with a CD4 cell 
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count change of less than 100 cells/μl. Clients who has a CD4 cell count change greater than 500 
cells/μl had 77% lower odds of death (OR= 0.229 [CI: 0.109-0.478]) compared to clients with a 
CD4 cell count change of less than 100 cells/μl. Clients with a baseline heomoglobin level of less 
than 8 g/dl had 3 times higher odds of death (OR= 3.131 [CI: 2.046-4.789]) compared to clients 
with a baseline greater than 8 g/dl.  
 
In relation to ART regimen, being on ZDV/3TC was used as the reference category because it was 
the regimen that most clients were on. Clients on DT4/3TC has a significantly 9 times higher odds 
of death (OR= 8.92 [CI: 6.61-12.03]) compared to clients on ZDV/3TC.  
 
Clients that had pulmonary TB had almost double the odds of death (OR=1.64 [CI: 1.27-2.11]) 
compared to clients that did not have pulmonary TB. Clients that had cryptococci meningitis while 
on HAART had more than double the odds of death compared to clients that did not have 
cryptococci meningitis (OR=2.38 [CI: 1.60-3.55]). Clients that had Kaposi Sarcoma while on 
HAART had almost 3 times higher odds of death compared to clients that did not have Kaposi 
sarcoma (OR 2.90 [CI: 1.58-5.30]). Clients that had esophageal candidiasis had almost double the 
odds of death while on HAART compared to clients that did not have esophageal candidiasis (OR= 
1.71 (CI: 1.58-2.30). While clients that had oral candidiasis had 1.5 times higher odds of death 
(OR= 1.47 [CI: 1.15-1.87]) compared to clients that did not have oral candidiasis. However, clients 
that had preurigo while on HAART had 51% lower odds of death compared to clients that did not 
have preurigo (OR =0.49 [CI: 0.39-0.63]). Female clients who got pregnant while on HAART had 
51% lower odds of death compared to clients that did not get pregnant (OR = 0.508[CI: 0.34-
0.76]).  
 
Adherence to ART, enrollment on PMTCT for pregnant HIV positive women, having low baseline 
level of hemoglobin (below 8g/dl), reported having opportunistic infections, in particular 
pneumocystis pneumonia, toxoplasmosis and extra-pulmonary TB, being on family planning were 
not significantly associated with five-year survival on ART.  
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Table 4.4: Five-year survival by clinical characteristics of study respondents (N=2,244) 
                             Characteristics Dead within 
5 years (%) 
Alive after 5 
years (%) 
Crude Odds Ratio 
(95% Confidence 
Interval) 
     
Length of time between 
diagnosis and ART 
initiation (years) 
<1  6.3 8.3 1.228 (0.929-1.639) 
1-2 41.6 42.0 1.105 (0.764-1.599) 
>2  34.9 34.8 Ref 
Baseline CD4 cell counts 
(cells/μl) 
<250 89.5 54.7 12.721 (5.607-28.858) 
250-500 8.6 30.5 2.181 (0.890-5.342) 
500+ 1.9 14.8 Ref 
CD4 cell counts change 
(cells/μl) 
<100  6.9 14.3 Ref 
100<250  3.5 24.5 0.171 (0.085-0.344) 
250-500 7.8 21.4 0.064 (0.023-0.175) 
500+ 81.9 38.8 0.229 (0.109-0.478) 
ART Adherence Yes 87.0 89.1 0.816 (0.571-1.168) 
Baseline hemoglobin 
(g/dl) 
<8 23.9 9.1 3.131 (2.046-4.789) 
8+ 79.1 90.9 Ref 
Experienced ART side-
effects 
Yes 28.3 25.4 1.157 (0.887-1.509) 
ART Regimen D4T/3TC 37.4 6.2 8.919 (6.611-12.033) 
TD4/3TC 8.6 13.8 0.917 (0.599-1.405) 
ZDV/3TC 54.0 79.9 Ref 
On first line Yes 95.5 95.8 1.212 (0.638-2.302) 
Opportunistic Infections Yes 13.8 15.3 1.125(0.817-1.550) 
Pulmonary TB Yes 35.6 25.2 1.638(1.273-2.109) 
Extra-pulmonary TB Yes 4.8 3.6 1.328(0.751-2.350) 
Preurigo Yes 54.9 71.2 0.491(0.385-0.626) 
Cryptococci meningitis Yes 11.8 5.3 2.384(1.603-3.545) 
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                             Characteristics Dead within 
5 years (%) 
Alive after 5 
years (%) 
Crude Odds Ratio 
(95% Confidence 
Interval) 
Kaposi Sarcoma Yes 5.1 1.8 2.896(1.583-5.297) 
Esophageal  Candida Yes 22.5 14.5 1.714(1.278-2.297) 
Oral Candida Yes 43.5 34.4 1.470(1.154-1.872) 
Pneumocystis Pneumonia  Yes 1.9 1.0 1.952(0.774-4.926) 
Toxoplasmosis Yes 3.2 5.0 0.626(0.323-1.214) 
Client on Family planning Yes 8.9 17.8 0.398(0.310-0.511) 
Client Pregnant Yes 19.4 32.2 0.508(0.342-0.757) 
Client on PMTCT Yes 6.1 20.6 0.248(0.058-1.054) 
 
4.2.2 Kaplan Meier and Cox Proportional Hazards Model 
Time to death were compared through survival analysis using the Kaplan-Meier method using the 
log-rank test. Cox proportional hazards regression models were used to estimate the magnitude of 
association by hazard ratios (HRs), with their respective 95%CIs. 
 
Figure 4.2 shows the Kaplan Meier survival curve by gender. Table 4.5 shows five-year survival 
by sociodemographic characteristics of ART clients. Female clients had a higher median survival 
of 353 (IQR: 120-1159) days compared with males with 240 (IQR: 84-824) days: (p=0.0295). The 
risk of death among female clients was 22% lower compared to male clients (HR= 0.78 [CI: 0.62-
0.98]).  No significant associations were observed between education, marital status, religion, 
source of income, age at diagnosis with HIV, age at initiation on HAART, used tobacco, alcohol 
and drug use and survival on HAART. 
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Figure 4.2: Kaplan–Meier survival curve by Gender of the respondents 
 
 
 
 
 
  
34 
 
Table 4.5: Five-year survival by sociodemographic characteristics of the study respondents 
(N=2,244)  
                              Characteristics Dead within 
5 years (%) 
Median 
Survival (IQR) 
Unadjusted hazard 
ratio 
Gender Female 54.0 353(120-1159) 0.776(0.617-0.976) 
Male 65.8 240(84-824) Ref 
Education None 12.4 301(110-822) Ref 
Primary 21.2 268(97-994) 0.838(0.576-1.220) 
Secondary 34.5 280(96-1006) 0.908(0.607-1.358) 
Tertiary Level 3.9 794(325-1336) 0.529(0.273-1.025) 
Marital status Single 6.8 422(169-1261) 0.709(0.410-1.226) 
Married 46.1 245(90-1006) 0.920(0.684-1.237) 
Separated 22.9 385(136-1021) 0.786(0.561-1.100) 
Divorced 2.6 201(116-589) 0.794(0.380-1.656) 
Widowed 21.6 347(95-923) Ref 
Other 1.6 875(719-1200) 0.715(0.288-1.775) 
Religion Anglican 31.4 341(112-1055) 0.976(0.679-1.402) 
Catholic 42.8 342(97-1022) 1.038(0.734-1.469) 
Muslim 11.8 175(78-499) 1.550(0.979-2.454) 
Other 14.1 338(98-1064) Ref 
Type of 
employment 
None 25.8 272(110-974) 0.979(0.648-1.479) 
Casual Laborer 31.8 234(98-732) 1.123(0.751-1.677) 
Housewife 3.8 325(109-1519) 0.847(0.406-1.766) 
Paid Employee 10.5 226(112-887) 1.151(0.686-1.930) 
Peasant 9.7 387(112-1064) 0.925(0.552-1.551) 
Student 1.1 499(126-779) 1.190(0.365-3.885) 
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                              Characteristics Dead within 
5 years (%) 
Median 
Survival (IQR) 
Unadjusted hazard 
ratio 
Vendor 13.1 212(78-1015) Ref 
Other 4.1 181(70-875) 0.924(0.468-1.825) 
Distance to health 
facility (km) 
1-5 22.5 325(90-1015) 1.106(0.550-2.223) 
6-10 20.9 330(116-1015) 1.131(0.563-2.271) 
11-20 17.6 269(62-822) 1.135(0.563-2.289) 
21-35 12.9 472(148-1261) 1.053(0.518-2.140) 
36-75 22.5 319(126-794) 1.280(0.617-2.656) 
>75 3.3 144(65-1250) ref 
Age at diagnosis 
(years) 
15-24 6.0 350(136-906) 0.899(0.471-1.714) 
25-34 41.6 225(92-747) 1.107(0.674-1.818) 
35-44 34.9 389(116-1012) 0.983(0.595-1.624) 
45-54 11.8 369(79-1434) 0.781(0.443-1.378) 
55+ 5.7 549(185-1059) ref 
Age at ART 
initiation (years) 
15-24 4.8 506(142-1055) 1.019(0.509-2.042) 
25-34 36.2 209(96-584) 1.366(0.818-2.279) 
35-44 39.7 385(116-1056) 1.012(0.608-1.685) 
45-54 14.0 386(88-1270) 0.905(0.514-1.594) 
55+ 5.4 548(86-1059) Ref 
Used tobacco  Yes 4.1 350(77-984) 1.138(0.770-1.680) 
No 95.9 319(103-1015) Ref 
Used Alcohol and 
Drugs  
Yes 9.5 350(97-1399) 0.553(0.105-2.901) 
 No 90.5 319(231-392)  
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Figure 4.3 shows Kaplan Meier survival curves for length of time between HIV diagnosis and 
initiation on HAART. Clients initiated on HAART within 1 year after diagnosis with HIV had a 
median survival time of 202 (IQR: 81-732) days; clients initiated on HAART between 1 year and 
2 years after diagnosis with HIV had median survival was 519 (IQR: 112-1057) days; and clients 
initiated after 2 years had median survival of 344 (IQR: 22-1635) days. Clients initiated on 
HAART within 1 year of diagnosis had almost twice the hazard of death compared to clients 
initiated 2 years after diagnosis with HIV (HR= 1.94 [CI: 1.21-3.10], this risk was significantly 
higher. 
 
 
Figure 4.3. Kaplan-Meier Survival curve by Length of time between Diagnosis and Initiation 
to HAART of the study respondents 
 
With regard to CD4 cell counts at diagnosis, clients with CD4 cell counts less than 250 cells/μl 
had a median survival time of 271(IQR: 96-887) days, clients with CD4 cell counts between 250 
cells/μl and 500 cells/μl had a median survival time of 758 (IQR: 177-1674) days, majority of 
clients with CD4 cell counts between 250 cells/μl and 500 cells/μl at diagnosis were still alive after 
10 years on HAART. Clients diagnosed at CD4 cell counts less than 250 cells/μl had almost 5 
times higher hazard of death compared to clients diagnosed at CD4 cell count greater than 500 
cells/μl (HR= 4.75 [CI: 1.77-12.78]), this difference was significant (p=0.0020).  
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Clients with CD4 cell counts change between the baseline and the highest CD4 attained of less 
than 100cells/μl  had a median survival time of 532 (IQR: 325-839) days; clients with CD4 cell 
counts change between 100 cells/μl  and 250 cells/μl had a median survival time of 504 (IQR:250-
1150) days, clients with CD4 cell counts change between 250 and 500 cells/μl had a median 
survival time of 1,659 days, majority of clients with CD4 change above 500 cells/μl were still alive 
so the median survival could not be computed. With regards to CD4 change (defined as the change 
in CD4 count between baseline CD4 and the highest CD4 attained over the client’s lifetime), 
clients who had a CD4 cell counts change of less than100 cells/μl and CD4 cell counts change 
between 100 cells/μl but less than 250 cells/μl both had a higher hazard of death compared to the 
reference category of CD4 cell counts change less than 100 cells/μl (HR= 0.24 [CI: 0.087-0.651]) 
and (HR= 0.45 [CI: 0.141-1.409]) and (HR= 2.34 [CI: 0.80-6.85]) respectively.  
 
Clients who were on DT4/3TC had a median survival time of 149 (IQR: 62-325) days; clients on 
TD4/3TC had a median survival time of 1,331 (IQR: 535-1,842) days; and clients on ZDV/3TC 
had a median survival time of 499 (IQR: 144-1250) days. Figure 4.4 shows the Kaplan Meier 
analysis of survival time and ART regiments. Significant association was observed between 
survival on HAART and regimen (p<0.0001). Compared to clients on ZDV/3TC based regimens, 
client on DT4/3TC had almost three times higher hazard of death (HR= 2.64 [CI: 2.04-3.41]). 
While clients on TD4/3TC a significantly 46% lower hazard of death: (HR= 0.54 [CI: 0.35-0.84]).  
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Figure 4.4. Kaplan–Meier survival curve by HAART Regimen 
 
Clients that had opportunistic infections had a median survival time of 165 (IQR: 73-699) days 
while those that did not have opportunistic infections had a median survival time of 341 (IQR: 
112-1056). Clients that had opportunistic infections while in HAART had a 1.4 times higher 
hazard of death compared to those that did not had opportunistic infections (HR= 1.45 [CI:1.07-
1.95] p= 0.0164). Clients that had pulmonary TB while on HAART had a median survival time of 
362(126-1329) days while clients that did not have pulmonary TB had a median survival time of 
280(96-867). Clients that had pulmonary TB had 1.4 times higher hazard of death (HR= 1.36 [CI: 
1.07-1.72]) compared to clients that did not have pulmonary TB while in HAART.  
 
Clients that had extra-pulmonary TB had a median survival time of 1006 (IQR: 134-1,803) days 
while those that did not have extra-pulmonary TB had a median survival time of 296 (98-949) 
days. Clients that had extra-pulmonary TB had 53% lower hazard of death compared to clients that 
did not have extra-pulmonary TB (HR= 0.47 [CI: 0.275-0.809]). Clients that had preurigo had a 
median survival time of 535 (IQR: 148-1391) days while those that did not have preurigo had a 
median survival time of 196 (IQR: 74-547). Clients that had preurigo had a 47% lower hazard of 
death while on HAART compared to clients that did not have preurigo (HR = 0.530 [CI: 0.419-
0.669]).  
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Clients that had pneumocystis pneumonia had a median survival time of 315 (IQR: 236-320) days 
while those that did not have pneumocystis pneumonia had a median survival time of 325 (IQR: 
97-1015). No significant association was observed between survival on HAART and pneumocystis 
pneumonia although clients that had pneumocystis pneumonia had 52% lower hazard of death 
(HR= 0.48 [CI: 0.249-0.940]) compared to clients that did not have pneumocystis pneumonia.  
 
Clients that had toxoplasmosis, had a median survival time of 1042 (362-1.963) days, while those 
that did not have toxoplasmosis had a median survival time of 296 (IQR: 97-984) days. Clients 
that had toxoplasmosis had a lower hazard of death compared to clients that did not have 
toxoplasmosis had a 52% lower hazard (HR= 0.48 [CI: 0.249-0.940]).  
 
Clients that had used family planning had a median survival time of 538 (IQR: 96-1535) days 
while those who had not used FP had a median survival time of 262 (IQR: 108-839). Client that 
had used FP had a significantly 30% lower hazard of death compared to not using family planning 
(HR= 0.701 [CI: 0.54-0.902]). 
 
No association was observed between ART adherence, baseline hemoglobin level , being on first 
line ART, preurigo, Cryptococci meningitis, Kaposi Sarcoma, esophageal candidiasis, oral 
candidiasis and hazard of death. 
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Table 4.6: Five-year survival by clinical characteristics of study respondents (N =2,244) 
                              Characteristics Dead within 
5 years (%) 
Median 
Survival (IQR) 
Unadjusted hazard 
ratio 
Length of time between 
diagnosis and ART 
initiation (years) 
<1  54.6 202(81-732) 1.937(1.210-3.102) 
1-2 18.6 519(112-1057) 1.240(0.744-2.066) 
>2  26.8 344(22-1635) ref 
Baseline CD4 cell counts 
(cells/μl) 
<250 89.5 271(96-887) 4.751(1.766-12.783) 
250-500 8.6 758(177-1674) 2.339(0.799-6.846) 
500+ 1.9 - Ref 
CD4 cell counts Change 
(cells/μl) 
<100  81.9 532(325-839) Ref 
100<250  7.8 504(250-115 0.238(0.087-0.651) 
250-500 3.5 1659(33-.) 0.445(0.141-1.409) 
500+ 6.8 1819 1.339(0.490-3.653) 
ART Adherence 
 
Yes 87.0 325(109-914) 1.189(0.848-1.666) 
No 13.0 139(33-1519) Ref 
Baseline Hemoglobin (g/dl) <8 23.9 331(56-1330) 1.330(0.888-1.990) 
8+ 79.1 785(181-1716) Ref 
ART Regimen D4T/3TC 10.6 149(62-325) 2.638(2.043-3.405) 
TD4/3TC 13.1 1331(535-1842) 0.541(0.348-0.839) 
ZDV/3TC 76.3 499(144-1250) Ref 
On first line Yes 95.90 276(97-939) 1.066(0.598-1.901) 
No 4.10 1519(1050-
1805) 
Ref 
Had Opportunistic 
Infections 
Yes 84.5 165(73-699) 1.355(1.065-1.724) 
No 15.5 341(112-1056) Ref 
Pulmonary TB Yes 35.6 362(126-1329) 0.472(0.275-0.809) 
No 64.4 280(96-867) Ref 
Extra-pulmonary TB Yes 4.8 1006(134-.) 0.530(0.419-0.669) 
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                              Characteristics Dead within 
5 years (%) 
Median 
Survival (IQR) 
Unadjusted hazard 
ratio 
No 95.2 296(98-949) Ref 
Preurigo Yes 54.9 535(148-1391) 0.893(0.630-1.266) 
No 45.1 196(74-547) Ref 
Cryptococci meningitis Yes 11.8 265(126-946) 0.861(0.512-1.448) 
No 88.2 330(97-1022) Ref 
Kaposi Sarcoma Yes 5.1 348(78-1015) 1.077(0.819-1.417) 
No 94.9 319(106-1015) Ref 
Esophageal Candida Yes 22.5 280(112-1015) 1.233(0.978-1.553) 
No 77.5 323(98-1010) Ref 
Oral Candida Yes 43.5 270(98-1184) 0.941(0.419-2.115) 
No 56.5 341(106-809) Ref 
Pneumocystis Pneumonia  Yes 1.9 315(236-320) 0.483(0.249-0.940) 
No 98.1 325(97-1015) Ref 
Toxoplasmosis Yes 4.7 1042(362-.) 0.701(0.54-0.902) 
No 95.3 296(97-984) Ref 
Client on Family planning Yes 52.90 538(96-1535) 1.937(1.210-3.102) 
No 47.1 262(108-839) Ref 
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4.4 Multivariate Analysis 
Two models were fitted to the data: logistic regression and cox proportional hazards regression 
model. A purposeful selection of predictor variables for the final multivariate analysis was done.  
The models included either variables that were tested to be significant at P ≤ 0.20 in univariate 
analyses (Hosmer, Lemeshow, & May, 2008) or which were pre-determined to be clinically 
important. P-values were two-sided and those P ≤ 0.05 were considered to be statistically 
significant.  Age at which the client was diagnosis with HIV and marital status were forced into 
the multivariate models based on a-priori assumptions of the importance of these variables. 
 
4.4.1 Logistic regression  
Table 4.7 shows the result of the multivariate logistic analysis and sociodemographic 
characteristics of the respondents. Females respondents were 13% times less likely to die within 5 
years of HAART initiation compared to the male clients AOR (0.87 [CI: 0.556-0.857] p=0.0366).   
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Table 4.7: Five year survival and sociodemographic characteristics of the study 
respondents (N=2,244)  
                             
Characteristics 
Dead within 
5 years (%) 
Alive after 
5 years (%) 
Crude Odds Adjusted Odds 
ratios 
Gender Female 54.0 46.0 0.610(0.479-0.776) 0.869(0.556-0.857) 
Male 65.8 34.2   
Education None 12.4 11.7 Ref  
Primary 
level 
55.7 54.7 0.963(0.659-1.409)  
Secondary 
level 
28.0 28.7 0.924(0.611-1.395)  
Tertiary 
level 
3.9 4.9 0.762(0.381-1.524)  
Marital status Single 5.2 5.3 1.067(0.594-1.920)  
Married 46.1 44.4 1.136(0.831-1.552)  
Separated 22.9 24.4 1.028(0.718-1.470)  
Divorced 2.6 1.5 1.906(0.834-4.357)  
Widowed 21.6 23.6 Ref  
Other 1.6 0.8 2.224(0.783-6.318)  
Religion Anglican 31.4 33.8 0.801(0.542-1.184)  
Catholic 42.8 42.6 0.867(0.596-1.261)  
Muslim 11.8 11.4 0.889(0.549-1.437)  
Other 14.1 12.1 Ref  
Type of 
Employment 
None 25.8 22.8 1.409(0.912-2.175)  
Casual 
Laborer 
31.8 27.7 1.491(0.979-2.270)  
Housewife 3.8 3.8 1.283(0.604-2.728)  
Paid 
Employee 
10.5 11.2 1.217(0.716-2.068)  
Peasant 9.7 11.7 1.078(0.629-1.849)  
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Characteristics 
Dead within 
5 years (%) 
Alive after 
5 years (%) 
Crude Odds Adjusted Odds 
ratios 
Student 1.1 0.4 3.032(0.769-11.964)  
Vendor 13.1 17.0 Ref  
OTHER 4.1 4.5 1.186(0.575-2.445)  
Distance to 
health 
facility(km) 
1-5 22.5 18.0 1.775(0.878-3.588)  
6-10 20.9 21.0 1.389(0.689-2.800)  
11-20 17.6 19.4 1.406(0.694-2.848)  
21-35 12.9 13.5 1.280(0.627-2.616)  
36-75 22.5 22.3 1.356(0.650-2.829)  
>75 3.3 4.7   
Age at 
diagnosis 
(years) 
15-24 6.0 8.3 0.475(0.235-0.959)  
25-34 41.6 42.0 0.646(0.373-1.118)  
35-44 34.9 34.8 0.655(0.376-1.140)  
45-54 11.8 11.1 0.692(0.371-1.290)  
55+ 5.7 3.7 Ref  
Age at ART 
initiation 
(years) 
15-24 4.8 5.2 0.803(0.379-1.700)  
25-34 36.2 38.5 0.821(0.472-1.429)  
35-44 39.7 38.3 0.905(0.522-1.572)  
45-54 14.0 13.3 0.920(0.501-1.691)  
55+ 5.4 4.7 Ref  
Used tobacco  
Yes 4.1 1.1 3.9111(1.93-7.89) 4.252(0.69-26.296) 
No 95.9 98.9   
Used Alcohol 
and drugs 
Yes 9.5 90.5 1.377(0.909-2.084)  
No 7.1 92.9   
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Table 4.8 shows the result of the multivariate logistic analysis of clinical characteristics of the 
respondents and five year survival.  
 
In relation to baseline CD4 clients, clients who has a CD4 cell count less than 250 cells/μl had 7 
times higher odds of death (AOR= 6.947 [CI: 2.882-16.744]) compared to clients with a baseline 
CD4 of greater than 500 cells/μl. Clients who has a CD4 cell count between 250 cells/μl and 500 
cells/μl had 3 times higher odds of death (AOR= 2.559 [CI: 1.004-6.520]) compared to clients with 
a baseline CD4 of greater than 500 cells/μl.  
 
Clients who had a CD4 cell count change of between 100-250 cells/μl had 93% lower odds of 
death (AOR= 0.047 [CI: 0.015-1.153]) compared to clients with a CD4 cell count change of less 
than 100 cells/μl. Clients who has a CD4 cell count change of between 250 cells/μl and 500 cells/μl 
had 80% lower odds of death (AOR= 0.196 [CI: 0.095-0.403]) compared to clients with a CD4 
cell count change of less than 100 cells/μl. Clients who has a CD4 cell count change greater than 
500 cells/μl had 80% lower odds of death A(OR= 0.200 [CI:0.092-0.434]) compared to clients 
with a CD4 cell count change of less than 100 cells/μl. Clients who suffered from side effects of 
HAART had a 3 times higher odds of death (AOR= 2.704 [CI: 1.683-4.344]) compared to clients 
who did not have any side effects from HAART. 
 
Client on DT4/3TC had almost 4 times higher adjusted odds of death: (AOR= 3.63 [CI: 1.893-
6.978]) compared to clients on ZDV/3TC based regimens, clients on TD4/3TC had almost 2 times 
higher adjusted odds of death: (AOR= 1.47 [CI: 0.829-2.596]) compared to clients on ZDV/3TC 
based regimens.  Clients that had pulmonary TB had almost 2 times adjusted odds of death 
compared to clients that did not have pulmonary TB (AOR= 1.75 [CI: 1.109-2.770]). Clients that 
had preurigo had a 49% lower adjusted odds of death while on HAART compared to clients that 
did not have preurigo (AOR= 0.510 [CI: 0.324-0.803]). Clients that had cryptococci meningitis 
had almost 3 times higher adjusted odds of death while on HAART compared to clients that did 
not have meningitis (AOR= 2.53 [CI:1.111-5.775]).  
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A non-significant association was observed between five year survival and baseline hemoglobin 
levels, having Kaposi Sarcoma, esophageal candidiasis, oral candidiasis; having used family 
planning clients who had low HB. 
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Table 4.8: Five year survival and clinical characteristics of the study respondents (N=2,244) 
                             Characteristics Dead 
within 5 
years (%) 
Alive 
after 5 
years (%) 
Crude Odds Adjusted Odds 
ratios 
Length of time 
between diagnosis 
and ART 
initiation (years) 
<1  6.3 8.3 1.228(0.929-1.639)  
1-2 41.6 42.0 1.105(0.764-1.599)  
>2  34.9 34.8   
Baseline CD4 cell 
counts (cells/μl) 
<250 89.5 54.7 12.721(5.607-
28.858) 
6.947(2.882-16.744) 
250-500 8.6 30.5 2.181(0.890-5.342) 2.559(1.004-6.520) 
500+ 1.9 14.8 Ref  
CD4 cell counts  
Change(cells/μl) 
<100  6.9 14.3 Ref  
100<250  3.5 24.5 0.171(0.085-0.344) 0.047(0.015-1.153) 
250-500 7.8 21.4 0.064(0.023-0.175) 0.196(0.095-0.403) 
500+ 81.9 38.8 0.229(0.109-0.478) 0.200(0.092-0.434) 
ART Adherence 
 
  
Yes 87.0 89.1 0.816 (0.570-1.168) 0.484(0.267-0.877) 
No 13.0 10.9   
Baseline 
hemoglobin level 
(g/dl) 
<8 23.9 9.1 3.131(2.046-4.789)  
8+ 79.1 90.9   
Experienced 
ART-effect 
Yes 28.3 25.4 1.157(0.887-1.509) 2.704(1.683-4.344) 
No 71.7 74.6   
ART Regimen 
D4T/3TC 37.4 6.2 8.919(6.611-12.033) 3.633(1.892-6.978) 
TD4/3TC 8.6 13.8 0.917(0.599-1.405) 1.467(0.829-2.596) 
ZDV/3TC 54.0 79.9 Ref  
On first line 
Yes 95.5 95.8 1.212(0.638-2.302)  
No 3.5 4.2 Ref  
Opportunistic 
Infections 
Yes 13.8 15.3 1.125(0.817-1.550)  
No 86.2 84.7   
Pulmonary TB Yes 35.6 25.2 1.638(1.273-2.109) 1.753(1.109-2.770) 
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                             Characteristics Dead 
within 5 
years (%) 
Alive 
after 5 
years (%) 
Crude Odds Adjusted Odds 
ratios 
No 64.4 74.8   
Extra-pulmonary 
TB 
Yes 4.8 3.6 1.328(0.751-2.350)  
No 95.2 96.4   
Preurigo 
Yes 54.9 71.2 0.491(0.385-0.626) 0.510(0.324-0.803) 
No 45.1 28.7   
Cryptococci 
meningitis 
Yes 11.8 5.3 2.384(1.603-3.545) 2.533(1.111-5.775) 
No 88.2 94.7   
Kaposi Sarcoma 
Yes 5.1 1.8 2.896(1.583-5.297) 2.169(0.663-7.092) 
No 94.9 98.2   
Esophageal  
Candida 
Yes 22.5 14.5 1.714(1.278-2.297) 8.830(0.424-1.623) 
No 77.5 85.5   
Oral Candida 
Yes 43.5 34.4 1.470(1.154-1.872) 1.467(0.911-2.363) 
No 56.5 65.6   
Pneumocystis 
Pneumonia  
Yes 1.9 1.0 1.952(0.774-4.926)  
No 98.1 99.0   
Toxoplasmosis 
Yes 3.2 5.0 0.626(0.323-1.214)  
No 96.8 95.0   
Client on Family 
planning 
Yes 8.9 17.8 0.398(0.310-0.511) 0.852(0.533-1.360) 
No 91.1 80.2   
Client Pregnant 
Yes 19.4 32.2 0.398(0.310-0.511)  
No 80.6 67.8   
Client on PMTCT 
Yes 6.1 20.6 0.248(0.058-1.054)  
No 93.9 79.4   
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4.4.2  Multivariate Cox regression analysis  
According to the results of the multivariate cox regression model (table 4.9), the sex of the clients 
was significantly associated with survival time on HAART. Female clients had a 12% lower risk 
of death compared to the male clients (aHR=0.88 [CI: 0.443-0.936]) this difference was significant 
(p=0.0356). Clients with primary education had 50% lower risk of death compared to clients with 
no education (aHR= 0.50 [CI: 0.217-1.102]) clients with secondary level education had 63% lower 
risk of death compared to clients with no education: (aHR= 0.27 [CI: 0.118-0.601]), clients with 
Higher Institution had 88% lower risk of death compared to clients with no education: (aHR =0.12 
[CI: 0.048-0.649-0.949]). Significant difference in survival time were observed between clients 
with secondary and higher institution level of education compared to clients with no education 
(p=0.0015; p=0.0090 respectively). 
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Table 4.9: Survival time and sociodemographic characteristics of the study respondents 
(n=2,244) 
                              Characteristics Dead 
within 5 
years % 
Alive 
after 5 
years % 
Unadjusted hazard 
ratio 
Adjusted hazard 
ratio 
                                                  
% 
  
Gender Female 54.0 46.0 0.776(0.617-0.976) 0.882(0.443-0.936) 
Male 65.8 34.2 Ref  
Education None 12.4 11.7 Ref  
Primary 21.2 21.1 0.963(0.659-1.409) 0.489(0.217-1.102) 
Secondary 26.4 25.9 0.924(0.611-1.395) 0.266(0.118-0.601) 
Higher 
Institution 
3.9 4.9 0.762(0.381-1.524) 0.117(0.048-0.649) 
Marital status Single 5.2 5.3 0.709(0.410-1.226)  
Married 46.1 44.4 0.920(0.684-1.237)  
Separated 22.9 24.4 0.786(0.561-1.100)  
Divorced 2.6 1.5 0.794(0.380-1.656)  
Widowed 21.6 23.6 Ref  
Other 1.6 0.8 0.715(0.288-1.775)  
Religion Anglican 31.4 33.8 0.976(0.679-1.402)  
Catholic 42.8 42.6 1.038(0.734-1.469)  
Muslim 11.8 11.4 1.550(0.979-2.454)  
Other 14.1 12.1 Ref  
Type of 
employment 
None 25.8 22.8 0.979(0.648-1.479)  
Casual Laborer 31.8 27.7 1.123(0.751-1.677)  
Housewife 3.8 3.8 0.847(0.406-1.766)  
Paid Employee 10.5 11.2 1.151(0.686-1.930)  
Peasant 9.7 11.7 0.925(0.552-1.551)  
Student 1.1 0.4 1.190(0.365-3.885)  
Vendor 13.1 17.0 Ref  
OTHER 4.1 4.5 0.924(0.468-1.825)  
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Distance to 
health 
facility(km) 
1-5 22.5 18.0 1.106(0.550-2.223)  
6-10 20.9 21.0 1.131(0.563-2.271)  
11-20 17.6 19.4 1.135(0.563-2.289)  
21-35 12.9 13.5 1.053(0.518-2.140)  
36-75 22.5 22.3 1.280(0.617-2.656)  
>75 3.3 4.7 ref  
Age at 
diagnosis 
(years) 
15-24 6.0 8.3 0.899(0.471-1.714)  
25-34 41.6 42.0 1.107(0.674-1.818)  
35-44 34.9 34.8 0.983(0.595-1.624)  
45-54 11.8 11.1 0.781(0.443-1.378)  
55+ 5.7 3.7 ref  
Age at ART 
initiation(years) 
15-24 4.8 5.2 1.019(0.509-2.042)  
25-34 36.2 38.5 1.366(0.818-2.279)  
35-44 39.7 38.3 1.012(0.608-1.685)  
45-54 14.0 13.3 0.905(0.514-1.594)  
55+ 5.4 4.7 Ref  
Used tobacco  Yes 4.1 1.1 1.066(0.598-1.901)  
 No 95.9 98.9   
Used alcohol 
and drugs 
Yes 9.5 90.5 1.138(0.770-1.680)  
 No 7.1 92.9   
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The result of the analysis between survival time and length of time between diagnosis and initiation 
into HAART, showed that clients initiated on HAART within 1 year and those initiated on 
HAART within 1 to 2 years after diagnosis with HIV both had higher risk of death compared to 
clients initiated on HAART more than 2 years after diagnosis with HIV.  Those initiated on 
HAART within 1 year after diagnosis with HIV had almost twice the risk of death compared to 
clients initiated more than 2 years after diagnosis: (aHR= 1.96 [1.006-3.821] p=0.0479); client 
initiated on HAART between 1 and 2 years after had almost double the risk compared to clients 
initiated on HAART more than 2 years after diagnosis with HIV: (aHR=1.83 [CI: 0.794-4.235]). 
Although client initiated on HAART between 1 and 2 years after diagnosis with HIV had almost 
two times the risk of death, this was also not significant (p=0.1558). 
  
Compared to clients on ZDV/3TC based regimens, client on DT4/3TC had a 5 times higher risk 
of death (aHR=4.79 [CI: 2.499-9.162] p=0.0003). While clients on TD4/3TC had 58% lower risk 
of death compared to clients on ZDV/3TC based regimens (aHR=0.42 [CI: 0.191-0.922] 
p<0.0001).  Clients that had suffered from an opportunistic infection had almost 4 times higher 
risk of death compared to those that had not suffered from opportunistic infections, (aHR= (3.65 
[1.603-8.291] p=0.002). Clients that suffered from pulmonary TB had 1.3 higher risk of death 
compared to clients that did not suffer from pulmonary TB (aHR=1.33 [CI: 1.162-2.733] 
p=0.0014). However, clients that had suffered from preurigo had 56% lower risk of death while 
on HAART compared to clients that had not suffered from preurigo (aHR=0.44 [CI: 0.236-0.744] 
p=0.0044).  
 
No significant association was observed between CD4 at diagnosis, extra-pulmonary TB, oral 
candidiasis, toxoplasmosis being on FP and risk of death while on HAART. 
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Table 4.10: Survival time and Clinical characteristics of study respondents (N=2,244) 
                              
Characteristics 
Dead 
within 5 
years % 
Alive 
after 5 
years % 
Unadjusted hazard 
ratio 
Adjusted hazard 
ratio 
Length of time 
between diagnosis 
and ART 
initiation (years) 
<1  6.3 8.3 1.937(1.210-3.102) 1.961(1.006-3.821) 
1-2 41.6 42.0 1.240(0.744-2.066) 1.833(0.794-4.235) 
>2  34.9 34.8   
Baseline CD4 cell 
counts (cells/μl) 
<250 89.5 54.7 4.751(1.766-12.783) 2.150(0.513-9.004) 
250-500 8.6 30.5 2.339(0.799-6.846) 1.435(0.349-5.898) 
500+ 1.9 14.8 Ref  
CD4 cell counts 
Change (cells/μl) 
<100  6.9 14.3 Ref  
100<250  3.5 24.5 0.238(0.087-0.651) 0.129(0.045-0.368) 
250-500 7.8 21.4 0.445(0.141-1.409) 0.778(0.237-2.559) 
500+ 81.9 38.8 1.339(0.490-3.653) 0.531(0.173-1.628) 
ART Adherence 
 
  
Yes 87.0 89.1 1.8889(0.933-3.823)  
No 13.0 10.9 Ref  
Baseline 
hemoglobin (g/dl) 
<8 23.9 9.1 1.330(0.888-1.990)  
8+ 79.1 90.9   
Experienced 
ART-effect 
Yes 28.3 25.4 0.624(0.477-0.817) 1.117(0.635-1.687) 
No 71.7 74.6   
ART Regimen D4T/3TC 37.4 6.2 2.638(2.043-3.405) 4.785(2.499-9.162) 
TD4/3TC 8.6 13.8 0.541(0.348-0.839) 0.420(0.191-0.922) 
ZDV/3TC 54.0 79.9 Ref  
Opportunistic 
Infections 
Yes 13.8 15.3 1.445(1.070-1.952) 3.645(1.603-8.291) 
No 86.2 84.7   
Pulmonary TB Yes 35.6 25.2 1.355(1.065-1.724) 1.332(1.162-2.732) 
No 64.4 74.8   
Extra-pulmonary 
TB 
Yes 4.8 3.6 0.472(0.275-0.809) 0.690(0.225-2.006) 
No 95.2 96.4   
Preurigo Yes 54.9 71.2 0.530(0.419-0.669) 0.438(0.236-0.744) 
No 45.1 28.7   
Cryptococci 
meningitis 
Yes 11.8 5.3 0.893(0.630-1.266)  
No 88.2 94.7   
Kaposi Sarcoma Yes 5.1 1.8 0.861(0.512-1.448)  
No 94.9 98.2   
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Characteristics 
Dead 
within 5 
years % 
Alive 
after 5 
years % 
Unadjusted hazard 
ratio 
Adjusted hazard 
ratio 
Oeso Candida Yes 22.5 14.5 1.077(0.819-1.417)  
No 77.5 85.5   
Oral Candida Yes 43.5 34.4 1.233(0.978-1.553) 1.121(0.432-1.193) 
No 56.5 65.6   
PNEUMOCYSTI
S PNEUMONIA  
Yes 1.9 1.0 0.941(0.419-2.115)  
No 98.1 99.0   
Toxoplasmosis Yes 3.2 5.0 0.483(0.249-0.940) 0.592(0.215-1.626) 
No 96.8 95.0   
On Family 
planning 
Yes 8.9 17.8 0.701(0.54-0.902) 1.244(0.758-2.040) 
No 91.1 80.2   
Client Pregnant Yes 19.4 32.2 0.508(0.3415-0.787)  
No 80.6 67.8   
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4.5 Summary 
This chapter presented results of the analysis data from respondents included in the study.  At the 
univariate level, gender, HB levels, having used tobacco, having had cryptococci meningitis, 
Kaposi sarcoma, esophageal or oral candidiasis were associated with five-year survival. Length of 
time between diagnosis and initiation into HAART, having suffered from opportunistic infections 
specifically extra pulmonary TB, toxoplasmosis, preurigo and using family planning were 
associated with survival time. At the multivariate level, factors associated with five-year survival 
included having tobacco use, having had cryptococci meningitis, Kaposi sarcoma, having had 
esophageal candidiasis, while those associated to survival time were; education, length of time 
between diagnosis and initiation into HAART and having had opportunistic infections. Factors 
that affected both five year and survival time included gender, baseline CD4 cell counts, CD4 cell 
counts change, ART regimen, having had pulmonary TB.  
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CHAPTER FIVE 
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
5.1 Introduction 
The main objective of the study was to investigate the effect of demographic, social-economic and 
health factors and changes in the health factors on five-year survival and survival time for patients 
initiated into HAART.  Two models were fitted to the data in order to achieve this objective.  This 
chapter presents the discussion, conclusion and recommendation from the findings in chapters 4 
and 5.  
 
5.2 Demographic and Socioeconomic characteristics associated with survival on HIV 
treatment  
The gender of the client was found to be associated with survival both at the bivariate level and at 
the multivariate level.  This finding is similar to those in other studies in which the female gender 
showed lower risk of mortality compared to males; a higher proportion of male client had died by 
the 5th year compared to women, and the male clients also had lower median survival compared to 
female clients.  Mixed results with regard to gender and survival on HAART have been shown, a 
study conducted in Cameroon to determine survival in AIDS patients on antiretroviral therapy in 
a rural center in the Far-North Province found male sex to be a predictor of mortality with a risk 
almost double that of female sex (HR= 1.73 [CI: 1.37–2.19]) (Isidore et al., 2009). Another study 
to evaluate gender-related mortality for HIV-infected patients on highly active antiretroviral 
therapy (HAART) in rural Uganda also found that female HIV-infected patients on HAART 
showed a tendency towards lower mortality after adjusting for baseline demographic variables and 
CD4 cell count (Alibhai et al., 2010).  A number of authors have also found gender differences in 
ART outcomes (Sterling et al., 2001; Moore et al., 2002; Kremer & Sonnenberg-Schwan 2003; 
Perez-Hoyos et al., 2003). However, some studies have found no association between gender and 
survival on HAART (Egger et al., 2002; Bourgeois et al., 2005; Nicastri et al., 2005; Braitstein et 
al., 2006).  Reasons for better survival by females was in a study in Thailand, that showed that 
women had more and earlier access to antiretroviral treatments (Le Coeur et al., 2007), which 
could explain better survival. In general, women have better health seeking behaviors than men. 
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The clients with the highest level of education had the higher median survival. The education level 
of the clients however did not significantly affect five-year survival on HAART. Education was 
found to significantly affect survival time; clients with higher level and lower primary level 
education having significantly lower risk of mortality compared to clients with no education. 
Implying that education of the client significantly affect survival at later stages of life. Mixed 
results have been found with the regard to education and mortality on HAART. The results in this 
study are similar to those  found in different countries that indicated that education beyond a high 
school degree was a statistically significant protective factor for all-cause and HIV/AIDS-related 
mortality (McDavid, Ling, Song, & Hall, 2008; Silverberg, Leyden, Quesenberry, & Horberg, 
2009), and one report showed no significant association with education. In this study education 
affected long term survival but not five-year survival implying that it affected survival in the long 
run, but not in the short term. The challenge that clients with no educated face could be the 
difficulty in reading and or understand medication instruction.  
 
In this study, both client age at diagnosis and the age at initiation on HAART were not significantly 
affect both the five-year survival and survival time. Other studies have found similar result, for 
example, age at sero-conversion seems to have become a less important prognostic factor for 
progression to AIDS since the introduction of HAART, yet it is known that reconstitution of 
immune function is likely to be more difficult in older people (Steinman, 1986).    However in this 
study, age was not an independent predictor of CD4 cell counts response to HAART unless at a 
threshold age of 50 years where according to studies they are less likely to have their CD4 cell 
counts increased during HAART (Grabar et al., 2004). 
 
According to a report published in the June 2006 American Journal of Public Health, tobacco 
smoking is associated with poorer response to antiretroviral therapy and worse disease progression 
in HIV/AIDS patients especially women.  An analysis of 924 participants starting HAART in the 
Women's Interagency HIV Study; showed that patients who smoked cigarettes had poorer 
virological and immunological response to HAART, lower CD4 cell counts, higher HIV viral 
loads, a 36% greater likelihood of developing AIDS-defining illnesses, and a 53% higher risk of 
death compared with non-smokers; however, the rate of specifically AIDS-related death was 
similar (Feldman et al., 2006).  These findings are similar to those in this study, patients who 
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reported having used tobacco had a lower median survival, a 3.9 higher risk of death, no significant 
association was observed between smoking and survival time. It should also be noted that although 
clients in this study had ever smoked, all of them reported not smoking after being diagnosed with 
HIV. In this study, although clients that consumed alcohol had a 1.3 and a 1.1 higher risk of death 
compared to clients that did not consume alcohol, these difference were not statistically significant. 
These findings are contrary to a number of studies that have found that heavy alcohol users 
receiving antiretroviral therapy were twice as likely to have CD4 cell counts below 500 than light 
or non-drinkers (OR 2.31 [CI: 1-5.5, p =0.03], and highly active antiretroviral therapy (HAART)-
treated heavy alcohol users were four times less likely to achieve a positive virological response 
(OR 4.13 [CI: 1.2-17, p=0.04] (Maria et al., 2003, Henrich et al., 2007).  
 
Marital status, religion, income of the clients, distance to the clinic were found not to significantly 
affect both the five-year survival and survival time. To date, research examining the role of SES 
on HIV/AIDS mortality has been scarce; according to Oakes and Rossi, this could be due to the 
difficulty of obtaining estimates of individual-level socioeconomic measures, the limited research 
could be due to measurement problems arising from the lack of conceptual clarity about the 
essential nature of social stratification and the absence of the application of sound measurement 
theory to the construction of socioeconomic measures in relation to health outcomes (Oakes & 
Rossi., 2003). The synthesis of the available up-to-date knowledge on the association between SES 
and mortality risk among people with HIV/AIDS indicates that SES affects patients’ survival to a 
different extent in various population groups at distinctive points of disease progression. 
 
5.2 Clinical factors associated survival on HIV treatment 
Length of time between diagnosis and ART initiation clinic were found to significantly affect the 
survival time but not five-year survival.  The shortest survival was observed for clients diagnosed 
and initiated within 1 year, implying that patients are identified late, when the disease has 
progressed. For survival time, before adjusting for other factors, client diagnosed and initiated 
within one year were twice more likely to die than those initiated later.  At the multivariate level 
they were almost 3 times more likely to die that those initiated later. Although initiation between 
1-2 years after diagnosis was associated with a higher hazard of death at the univariate level of 
analysis, the association was not significant at the multivariate level. Clients with CD4 cell counts 
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less than 250 cells/μl at diagnosed were found to have shorter survival, and were 7 times more 
likely to die within five years of diagnosis compared to those with CD4 cell counts greater than 
500 cells/μl, while those with CD4 cell counts between 250 cells/μl and 500 cells/μl were 3 times 
more likely to die within five years of diagnosed compared to those with CD4 cell counts greater 
than 500 cells/μl. Baseline CD4 cell counts however did not affect survival time. The implication 
of this is that in the CD4 cell counts at diagnosed matter in the short term, this period is also the 
time when most death occur.  
 
Although clients who were adherent had a higher median survival than patients who were not 
adherent, no significant association was observed between both the five year survival and survival 
time and adherence.  Two studies conducted in Ethiopia and Malawi however revealed contrary 
results in which poor adherence at the initiation of HAART had significant association with 
mortality (Bedru & Worku, 2010) and Malawi (Zachariah et al., 2006). The reason could be due 
to the fact that majority of clients were adherent to ART.  With increased adherence counselling 
which have been adopted in most countries as a standard of care, adherence levels have increased 
significantly. 
 
Clients with normal hemoglobin levels at initiation had higher median survival that those who had 
lower levels.  However, no significant association was observed between both the five year 
survival and survival time and HB levels at initiation.  The regimen with the higher median survival 
was TD4/3TC, followed by ZDV/3TC and lastly D4T/3TC.  The regimen the client was on affected 
both five year and survival time; while clients on D4T/3TC were 5 times more likely to die than 
clients on ZDV/3TC; being on TD4/3TC was found to be protective, with the probability of death 
as low as 37% less than for clients on ZDV/3TC. The finding of this study is similar to those of 
other studies. For example an evaluation study conducted in Serbia and Montenegro found that the 
use of regimens containing PIs and two NRTIs was associated with long-term survival (OR= 9.0, 
[CI 2.2-35.98], P<0.001) (Jevtović et al., 2007). Simultaneous use of all three drug classes was 
also predictive of long-term survival (OR= 7.4 [CI 2.2-25.1] P<0.001). In the same study, long 
time survivors took more drugs (P<0.001) and had more regimen switching than patients who 
died. Use of HAART composed of three NRTIs or NRTIs with an NNRTI did not differ between 
subgroups, while the use of classic HAART (two NRTIs+one PI) and HAART composed of all 
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three drug classes was significantly more common in the LTS subgroup (P=0.04 and 0.02, 
respectively). 
 
Overall, clients that had opportunistic infections have significantly lower median survival 
compared to those that did not have any opportunistic infections. From the logistic regression, 
client that had opportunistic infections were 1.4 times more likely to die compared to those who 
did not, however no difference were observed at the multivariate level.  It was also noted that 
having opportunistic infections did not affect survival time implying that opportunistic infections 
had an impact on survival in the short term.  With regards to specific opportunistic infections, 
pulmonary TB and preurigo affected both five year and survival time. Being on family planning 
was found to affect both five-year survival and survival time. Being on family planning was found 
to be protective in both cases.  
 
5.3 Summary 
1. With regard to objective one of the study, gender of the client affected both five year survival 
and survival time after initiation on HAART. The education level of the clients had marginal effect 
at the bivariate level of analysis for survival time, however after adjusting for other factors, having 
no education, having secondary level education had higher risk for death while having a higher 
level of education was protective. 
 
2. To determine social economic factors associated with long term survival of patients on HAART 
The education level of the clients had marginal effect at the bivariate level of analysis for survival 
time, however after adjusting for other factors having no education, senior 1-4 had higher risk for 
death while having a higher level of education was protective, having used tobacco also had an 
impact on survival. 
 
3. To determine biomedical factors associated with long term survival of patients on HAART: 
Several biomedical and behavioral factor affected survival: length between diagnosis and initiation 
into HAART, CD4 cell counts at initiation, HB at initiation, ART regimen, having opportunistic 
infections: in particular, pulmonary TB, extra pulmonary TB, preurigo, cryptococci meningitis, 
kaposi sarcoma, esophagus and oral candidiasis, toxoplasmosis and being on family planning.  
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4. To determine how changes in key biomedical parameter impact on survival of patients on 
HAART; Changes in biomedical factors evaluated was change in CD4 cell counts between at 
initiation and the maximum CD4 cell counts attained thereafter by the client.  The CD4 cell counts 
change affected both five-year survival and survival time in particular increase in CD4 cell counts 
was found to be protective.  
 
5.4 Conclusions 
This 10-year retrospective cohort study of AIDS patients on HAART provides insight in survival 
and its determinants in a non-governmental organization (NGO) managed setting. There are 
several predictors of mortality for patients on ART and although these determinants tend to be 
similar across the world, there are some striking differences in their relative frequency, e.g. the 
much lower baseline CD4 cell counts of patients starting ART in poor countries (Egger, 2007). 
Identifying the demographic, social economic, behavioral and biomedical variables, including how 
changes over time in these factors influence patient’s survival after initiation on HAART improves 
understanding of the HAART program. Knowledge of these factors facilitates the identification of 
patients predisposing to dying early and therefore strategies to prolong their survival can be put in 
place. This knowledge therefore provides practical implications for managing HIV infected 
patients on ART in Uganda and other resource-limited settings. 
 
5.5  Limitations 
The limitation of this study was that the data being was from routine data collected during service 
provision to HIV positive patients under the care of TASO, usually such data are not consistently 
collected and the detail of the data collected was not defined in a way that applied to the definition 
as required in this study. This was overcome in this study through the creation of new variables 
were possible to suit the objectives of the study. 
 
5.6 Recommendations 
Length of time between diagnosis and ART initiation affected survival.  The world health 
organization recommended earlier initiation of HIV+ patients into ART, this can only be possible 
if HIV positive patients are identified early. This will require that the government puts in place 
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strategies to test and identify people who are HIV positive and put in place mechanisms to link 
them into care.  The biggest gap is at community level, there is need to strengthen linkage between 
the communities and the health facilities.  
 
This study revealed that gender of the client affected survival of clients on HAART, with the 
female gender having better survival than male.  The poor health seeking behavior of men may be 
a contributing factor and strategies need to be put in place to encourage male HIV+ clients to seek 
medical care earlier. Enhanced counselling should be provided to men and male friendly service 
made available.  
 
The education level of clients is a predictor of mortality. It would be important that materials are 
translated into languages that clients understand and posters using pictures used to aid 
understanding especially for clients with low level of education. 
 
Although in the long run having any opportunistic infections increases the risk of death, for patients 
newly initiated, health workers should be vigilant in the identification and treatment of all 
opportunistic infections but specifically pulmonary TB, preurigo, cryptococci meningitis, kaposi 
sarcoma, esophagus and oral candidiasis.  
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APPENDIX I: Data Extraction Form 
Patient ID _____________ 
A. Demographic data 
Date of Birth …./…../………….. 
Date of diagnosis…./…../…………..  Age at diagnosis…………………………… 
Date of initiation into HAART …./…../…………Age at initiation of HAART…………… 
Was client on cotrimozaxole before HAART initiation Yes [   ]    No [   ] 
Residence: ___________________________Distance from TASO_________________Kms 
    
(Circle the appropriate code in the table below) 
 
7. Has the client ever smoked cigarettes?  Yes [   ]   No [   ] 
8. Is the client currently smoking cigarettes?  Yes [   ]   No [   ] 
9. Does the client drink alcohol?  Yes [   ]   No [   ] 
B: Biomedical Factors at diagnosis and enrollment into HAART 
3. Marital Status:   
 
1. Married Mono.     
2. Married Poly 
3. Cohabiting 
4. Separated 
5. Divorced 
6. Widowed 
7. Never Married 
8. Minor 
 
4. Sources of 
Income:     
1. None  
2. Paid employee 
3. Peasant 
4. Casual Laborer   
5. Housewife 
6.  Vendor/Business 
person 
7. Dependent  
99. Other (Specify 
5. Education Level: 
 
1. None 
7. Pre Primary 
2. Lower Primary (P1-P4) 
3. Upper Primary (P5 - P7) 
4. Senior 1 - 4 
5. Senior 5 - 6 
6. Higher Inst. Of Learning 
99. Other (Specify) 
 
6. Religion:   
 
1. Catholic 
2. Anglican 
3. Muslim  
4. S.D.A 
5. Pentecostal 
6. Orthodox 
99. Other (Specify) 
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                         At diagnosis At initiation on 
HAART 
Lowest ever 
attained 
Highest ever 
attained 
CD4 cell counts     
Viral load     
Hemoglobin     
BMI     
 
C: FAMILY PLANNING (Tick or Circle the appropriate response) 
i) Is the Client Pregnant?   
1. Yes…..  
2. No………………… 
 
ii) If Yes, Is Client on PMTCT?  
1. Yes…..  
2. No………………… 
 
ii) If NOT pregnant, is Client on any contraceptive method?  
1. Yes…..  
2. No………………… 
3. N/A…………………………. 
 
iv) Type of Family planning method  
1. Condoms  
2.  Oral Pill 
3.  Depo. (Injection)  
4. Implants 
5. Other (specify)……………………………………. 
D: ART MONITORING (Tick or Circle the appropriate response) 
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i) Is client on ARVs?  Yes [    ]     No [    ]   New [    ]   Restarting [    ]   Changed Regimen 
[    ]     
ii) If YES Current ARV Regimen Code _____________________  
iii) If CHANGED regimen please specify all other regimen taken before___________ 
 
E: SIDE EFFECTS OF ARVs 
1. None     
2. Anaemia     
3. Neuropathy   
4. Skin rash      
5. Jaundice      
6. Others(Specify) ________________________ 
F:  NEW OPPORTUNISTIC INFECTIONS 
OPPORTUNISTIC 
INFECTIONS 
Date1 Date2 Date3 
1. Cryptococcal Meningitis       
 2.  KS                   
 3. Pneumocystis Pneumonia                 
 4. Oesophageal Candidiasis         
5. Toxoplasmosis                
6. Extra PTB     
7. Cryptosporidium                   
 8. Recurrent oral 
Candidiasis            
   
9. Prurigo                
10. PTB                      
11. None       
12. Others(Specify)    
  
G: ADHERENCE 
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i) Has the client ever miss out taking the ARVs? Yes  [    ]     No  [    ]    
ii) If yes, please fill in the table below:  
Reasons for missing: 
1. No supplies     
2. Side effects     
3. Forgot    
 4. Shared      
 5 Discontinued,   Why? _______________________________________   
 6. Study Interruption         
7. No Transport        
8. Other (Specify) ____________________________  
 
Date  Reasons for missing (use the codes above fill in all that applies) 
  
  
 
H: Survival status 
i) What is the survival status of the client? 
1. Dead    
2.  Alive 
 
ii) If DEAD, indicate date of death ………/…../…… 
iii) If known, what was the cause (s) of death …………………………………………… 
 
 
 
 
 
